var title_f38_11_39088="Ferroportin hepcidin function";
var content_f38_11_39088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Interactions between hepcidin and ferroportin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates the iron export function of ferroportin in macrophages. This function (in blue, A) is regulated, in part, by the iron regulatory protein hepcidin (red circle), which binds to ferroportin (B), causing the complex to be internalized and degraded (C), preventing iron export. When hepcidin is in excess, dietary iron absorption is decreased by blocking iron export from intestinal brush border cells; iron export from macrophages is also blocked, leading to hypoferremia. When hepcidin levels are deficient, as in hereditary hemochromatosis, iron absorption proceeds without effective inhibition, leading to iron overload. Two types of ferroportin mutation are known. In one, ferroportin's iron export function is reduced, leading to accumulation of iron in macrophages and low transferrin saturation (D). In the second, hepcidin binding to ferroportin is impaired (E), leading to uncontrolled iron absorption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn after Andrews, N. Ferroportin hemochromatosis - One molecule, two diseases. The Hematologist 2005; 2:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39088=[""].join("\n");
var outline_f38_11_39088=null;
var title_f38_11_39089="Mycobacterium fortuitum skin infection";
var content_f38_11_39089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycobacterium fortuitum skin infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulceration and surrounding cellulitis of the neck caused by M. fortuitum. Courtesy of Charles V Sanders, MD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. p.146.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39089=[""].join("\n");
var outline_f38_11_39089=null;
var title_f38_11_39090="Acute ataxia in children";
var content_f38_11_39090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Algorithmic approach to acute ataxia in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 647px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * MRI preferred over CT if available in a timely fashion.",
"     <br>",
"      &bull; Papilledema, headache, and/or vomiting.",
"      <br>",
"       &Delta; Lumbar puncture may be considered.",
"       <br>",
"        &loz; This is a diagnosis of exclusion. Consider CT.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39090=[""].join("\n");
var outline_f38_11_39090=null;
var title_f38_11_39091="LEVOleucovorin: Patient drug information";
var content_f38_11_39091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   LEVOleucovorin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     see \"LEVOleucovorin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6268764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fusilev&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with methotrexate to avoid side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692160",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may lower the side effects of some drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with fluorouracil to help fight colorectal cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levoleucovorin, leucovorin, folic acid, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia caused by a lack of vitamin B",
"       <sub>",
"        12",
"       </sub>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12044 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-C04F1AFADF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39091=[""].join("\n");
var outline_f38_11_39091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6268764\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019819\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019821\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019820\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019825\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019826\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019828\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019823\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019824\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019830\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=related_link\">",
"      LEVOleucovorin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39092="Radiographs of depressed skull fracture";
var content_f38_11_39092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Depressed skull fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depressed skull fracture with intracerebral hemorrhage. A) Lateral radiograph shows a comminuted depressed fracture in the parietal region (arrows). B) CT image using bone windows shows the depressed fragment (arrow). C) Same image using brain windows shows multiple areas of intracranial hemorrhage (arrows) adjacent to the fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39092=[""].join("\n");
var outline_f38_11_39092=null;
var title_f38_11_39093="Recombinant hemagglutinin influenza vaccine: Drug information";
var content_f38_11_39093=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Recombinant hemagglutinin influenza vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/36/23109?source=see_link\">",
"    see \"Recombinant hemagglutinin influenza vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16226372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Influenza Virus Vaccine",
"     </span>",
"     <span class=\"collapsible-date\">",
"      2012-2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The 2012-2013 influenza virus vaccine contains the same H1N1 virus as in the 2011-2012 vaccine, but different H3N2 and B viruses. The vaccine strains approved for this season in the United States are as follows: A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, and B/Wisconsin/1/2010-like virus. Because immunity to influenza virus declines over time, and because two of the three strains of the virus are different this year than last, persons should be vaccinated every year even if vaccinated during the previous season.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In addition, a variant influenza A virus (H3N2v) is currently circulating in pigs and infecting humans. Immunization with the 2012-2013 seasonal influenza vaccine is not expected to provide protection against this virus.  Symptoms of H3N2v are generally similar to those of seasonal influenza infections.  Unfortunately, standard tests used to detect influenza virus cannot differentiate between H3N2v virus from seasonal influenza A (H3N2) virus and there is a potential for false negatives with antigen detection tests. Clinicians who suspect probable H3N2v virus should contact their local or state health department for additional testing for H3N2v at a state public health laboratory. A link to recent swine exposure (within 1 week) of symptom onset should be considered a probable H3N2v case. Antiviral treatment of H3N2v influenza is the same as seasonal influenza.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       FDA approves vaccines for the 2012-2013 influenza season:",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       CDC, Interim Information about Human Infections with H3N2v Virus:",
"       <a href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\" target=\"_blank\">",
"        file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16226377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flublok&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16226381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Recombinant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16226414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available  (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Flublok&reg;: I.M.: Adults 18-49 years: 0.5 mL/dose (1 per season)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16226415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for use in adults &gt;49 years of age",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16226416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16226417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16226380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16226418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     For I.M. administration only. Inspect for particulate matter and discoloration prior to administration. Adults should be vaccinated in the deltoid muscle. Do not inject into the gluteal region or areas where there may be a major nerve trunk. Shake gently prior to use. Avoiding use if visible particles are present in the solution after shaking.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Unless otherwise indicated in product labeling, jet injectors should",
"     <b>",
"      not",
"     </b>",
"     be used to administer inactivated influenza vaccines (FDA, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered  by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. However, in general, vaccination should not be deferred if the brand name or route of the previous dose is not available or not known (CDC, 2011). Adults should be vaccinated while seated or lying down (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16226385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to influenza virus strains contained in the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F16226373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16226395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Pain (37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Redness (4%), Swelling (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 2%), nasal congestion (1% to 2%), nasopharyngitis (1% to 2%), pharyngolaryngeal pain (1% to 2%), rhinorrhea (1% to 2%), upper respiratory tract infection (1% to 2%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16226391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe allergic reaction to any component of the vaccine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16226392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever) (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Antigenic response may not be as great as expected in HIV-infected persons with CD4 cells &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"     and viral copies of HIV type 1 &gt;30,000/mL (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP, as well as the Canadian National Advisory Committee on Immunization (NACI), recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely-immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroid]); may have a reduced response to vaccination (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children 6 months to &lt;3 years of age showed a decreased response to Flublok&reg; suggesting that it would not be effective. Flublok&reg; is not currently approved for children &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flublok&reg; is a trivalent influenza vaccine produced using continuous insect cell lines. It is a recombinant hemagglutinin (rHA) vaccine; it does not use the influenza virus or eggs in its production process.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16226386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16226387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnant women are at an increased risk of complications from influenza infection (Rasmussen, 2008). Inactivated influenza vaccination is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine. Information related to Flublok&reg; in pregnancy is not yet available. Pregnant women should observe the same precautions as nonpregnant women to reduce the risk of exposure to influenza and other respiratory infections. When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to the influenza vaccine during pregnancy to the",
"     <i>",
"      Vaccines and Medications in Pregnancy Surveillance System",
"     </i>",
"     (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972. Women exposed to Flublok&reg; during pregnancy may also be enrolled in the Protein Sciences Corporation registry (888-855-7871).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16226388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16226390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be used if administered to breast-feeding women. Recombinant vaccines do not affect the safety of breast-feeding for the mother or the infant  (CDC, 2011). When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16226422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16226406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the U.S. Public Health Service. Preparations from previous seasons must not be used.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-8):1-62. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/20689501/pubmed\" id=\"20689501\" target=\"_blank\">",
"        20689501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cox MM, Patriarca PA, and Treanor J, \"FluBlok, A Recombinant Hemagglutinin Influenza Vaccine,\"",
"      <i>",
"       Influenza Other Respi Viruses",
"      </i>",
"      , 2008, 2(6):211-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/19453397/pubmed\" id=\"19453397\" target=\"_blank\">",
"        19453397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson CE, \"Development of a Novel Recombinant Influenza Vaccine In Insect Cells,\"",
"      <i>",
"       Biologicals",
"      </i>",
"      , 2008, 36(6):350-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/18804387/pubmed\" id=\"18804387\" target=\"_blank\">",
"        18804387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Advisory Committee on Immunization (NACI), &ldquo;Statement on Seasonal Influenza Vaccine for 2011-2012,&rdquo;",
"      <i>",
"       Can Commun Dis Rep",
"      </i>",
"      , 2011, 37(ACS-5):1-55. Available at file://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-5/index-eng.php",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rasmussen SA, Jamieson DJ, and Bresee JS, \"Pandemic Influenza and Pregnant Women,\"",
"      <i>",
"       Emerg Infect Dis",
"      </i>",
"      , 2008, 14(1):95-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/18258087/pubmed\" id=\"18258087\" target=\"_blank\">",
"        18258087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treanor JJ, El Sahly H, King J, et al, \"Protective Efficacy of a Trivalent Recombinant Hemagglutinin Protein Vaccine (Flublok&reg;) Against Influenza in Healthy Adults: A Randomized, Placebo-Controlled Trial,\"",
"      <i>",
"       Vaccine",
"      </i>",
"      , 2011, 29(44):7733-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39093/abstract-text/21835220/pubmed\" id=\"21835220\" target=\"_blank\">",
"        21835220",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, &ldquo;FDA Updated Communication on Use of Jet Injectors With Inactivated Influenza Vaccines&rdquo;, October 26, 2011. Available at",
"      <a href=\"file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm\" target=\"_blank\">",
"       file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88426 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39093=[""].join("\n");
var outline_f38_11_39093=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226372\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226377\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226381\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226414\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226415\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226416\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226417\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226418\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226385\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226373\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226395\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226391\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226392\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226386\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226387\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226388\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226390\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226422\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16226406\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/36/23109?source=related_link\">",
"      Recombinant hemagglutinin influenza vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39094="Vulvar necrotiz fasciitis";
var content_f38_11_39094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar necrotizing fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraoperative photograph of necrotizing fasciitis of the vulva. The catheter notes the location of the urethra. Note the extent of the dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy;2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39094=[""].join("\n");
var outline_f38_11_39094=null;
var title_f38_11_39095="Cystic fibrosis: Genetics and pathogenesis";
var content_f38_11_39095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Genetics and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     Julie P Katkin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39095/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/11/39095/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is a multisystem disease affecting the digestive system, sweat glands, and the reproductive tract, but progressive lung disease continues to be the major cause of morbidity and mortality. Patients with CF have abnormal transport of chloride and sodium across the respiratory epithelium, resulting in thickened, viscous airway secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Over a highly variable time course ranging from months to decades after birth, individuals eventually develop chronic infection of the respiratory tract with a characteristic array of bacterial flora, leading to progressive respiratory insufficiency and eventual respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetics and pathogenesis of cystic fibrosis are discussed here. Details of the clinical manifestations and effects of the disease process are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=see_link\">",
"     \"Cystic fibrosis: Overview of gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CF is caused by mutations in a single large gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. Clinical disease requires disease-causing mutations in both copies of the CFTR gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The normal CFTR gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;CFTR belongs to the ABC (",
"    <strong>",
"     A",
"    </strong>",
"    TP-",
"    <strong>",
"     B",
"    </strong>",
"    inding",
"    <strong>",
"     C",
"    </strong>",
"    assette) family of proteins, a large group of related proteins that share transmembrane transport functions. ABC proteins include bacterial transporters for amino acids and other nutrients, surfactant transport proteins, and the mammalian multidrug resistance (MDR) protein (or P-glycoprotein).",
"   </p>",
"   <p>",
"    CFTR functions as a regulated chloride channel, which, in turn, may regulate the activity of other chloride and sodium channels at the cell surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The CFTR gene spans 250 kilobases on chromosome 7, encoding 1480 amino acids in the mature protein (",
"    <a class=\"graphic graphic_figure graphicRef60265 \" href=\"mobipreview.htm?15/43/16063\">",
"     figure 1",
"    </a>",
"    ). The protein has two groups of six membrane-spanning regions, two intracellular nucleotide-binding folds (NBFs), and a highly charged \"R domain\" containing multiple phosphorylation sites. Activation of the chloride channel requires phosphokinase A-mediated phosphorylation of the R domain, and the continuous presence of ATP in the NBFs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic changes in CFTR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenotypic expression of disease varies widely, primarily as a function of the specific mutation (or mutations) present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://www.genet.sickkids.on.ca/cftr/\">",
"     Cystic Fibrosis Mutation Database",
"    </a>",
"    lists more than 1300 different mutations in the CFTR gene with potential to cause disease.",
"   </p>",
"   <p>",
"    The most common mutation is delta F508 (deletion of three DNA bases coding for the 508th amino acid residue phenylalanine), which is found in approximately 70 percent of Caucasian patients with CF in the United States. Certain mutations are found at higher frequency in some ethnic groups because of apparent founder effects. As an example, five mutations account for an estimated 97 percent of CF alleles in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/22\">",
"     22",
"    </a>",
"    ]. A subset of the most frequent CFTR mutations is recommended for initial testing since the majority of individual mutations are very rare (",
"    <a class=\"graphic graphic_table graphicRef65637 \" href=\"mobipreview.htm?35/38/36459\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link&amp;anchor=H22#H22\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Molecular diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations of the CFTR gene have been divided into five different classes (",
"    <a class=\"graphic graphic_figure graphicRef80517 \" href=\"mobipreview.htm?23/6/23663\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/2,24\">",
"     2,24",
"    </a>",
"    ]. In general, mutations in classes I to III cause more severe disease than those in classes IV and V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. However, the clinical implications of a specific combination of mutations are often unclear, perhaps because of the influence of gene modifiers. Genotype-phenotype correlations are weak for pulmonary disease in CF, and somewhat stronger for the pancreatic insufficiency phenotype. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Gene modifiers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In most cases, specific mutations should not be used to make assumptions about the severity of disease in an individual patient. Knowledge of the mutations may be useful to guide initial therapy, but clinical decisions should be guided by observable parameters of growth, lung function, and nutritional status. Some investigational therapies are directed at specific classes of CFTR mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=see_link&amp;anchor=H3393763#H3393763\">",
"     \"Cystic fibrosis: Investigational therapies\", section on 'Reversing the consequences of CFTR mutations on protein function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Class I mutations: Defective protein production",
"    </span>",
"    &nbsp;&mdash;&nbsp;This defect is usually caused by nonsense, frameshift, or splice-site mutations, leading to premature termination of the mRNA and complete absence of CFTR protein. Examples include G542X, W1282X, R553X, 621+G&gt;T, and 1717-1G&gt;A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/25\">",
"     25",
"    </a>",
"    ]. This type of mutation accounts for two to five percent of cystic fibrosis cases worldwide. Some populations have a much higher frequency; as an example, 60 percent of Ashkenazi Jews with CF carry at least one copy of a nonsense mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Class II mutations: Defective protein processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class II mutations in the CFTR sequence cause abnormal post-translational processing of the CFTR protein, which prevents the protein from trafficking to the correct cellular location. This category includes the delta F508 (F508del) mutation, which accounts for 70 percent of the disease-causing alleles in the United States. Fifty percent of CF patients are homozygous for F508del, and 90 percent will carry at least one copy of this mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/25\">",
"     25",
"    </a>",
"    ]. N1303Lys (N1303K) and A455E are also class II mutations; the latter is associated with relatively mild lung disease and pancreatic sufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Class III mutations: Defective regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class III mutations lead to diminished channel activity in response to ATP. Many involve alterations of the NBF regions, NBO1 and NBO2, which may retain varying degrees of sensitivity to nucleotide binding (",
"    <a class=\"graphic graphic_figure graphicRef80517 \" href=\"mobipreview.htm?23/6/23663\">",
"     figure 2",
"    </a>",
"    ). Other CFTR mutations, mapped to the R domain, may also fall into this category. G551D is the most common class III mutation in Caucasian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/25\">",
"     25",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Class IV mutations: Defective conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;With class IV mutations, the protein is produced and correctly localized to the cell surface. However, although chloride currents are generated in response to cAMP stimulation, the rate of ion flow and the duration of channel opening are reduced when compared to normal CFTR function. R117H is the most common class IV mutation in Caucasian populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Class V mutations: Reduced amounts of functional CFTR protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;This class of mutation is not included in some schemes. It includes mutations that alter the stability of mRNA and others that alter the stability of the mature CFTR protein (the latter is sometimes classified separately into a Class VI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The mutation A455E has been classified as Class II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/25\">",
"     25",
"    </a>",
"    ] or Class V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/19,29,30\">",
"     19,29,30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENE MODIFIERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inconsistent association between CF genotypes and phenotypes points to a role for gene modifiers. These genetic variations are not directly related to the CFTR gene but affect the severity or clinical manifestations of disease. Research into a variety of candidate genes is ongoing. There is good evidence that the following genes act as modifiers in CF, and that approximately 20 percent of patients with classic CF carry variants in one or both of these genes that exacerbates the pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TGF-beta 1 &mdash; Transforming growth factor-beta (TGF-beta) is a potent suppressor of T cell activation and can decrease T cell proliferation and cytokine production. In a study of 808 patients who were homozygous for the delta F 508 mutation, polymorphisms in the TGF-beta 1 gene were associated with more severe CF lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4231?source=see_link\">",
"       \"Role of cytokines in the immune system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MBL &mdash; Mannose-binding lectin is an important component of the complement system, and deficiencies in this protein increase the risk for pyogenic infections. In individuals with CF, variant MBL alleles are associated with reduced lung function, increased risk for chronic Pseudomonas aeruginosa and Burkholderia cepacia complex infections, and early death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/33\">",
"       33",
"      </a>",
"      ]. In young patients with CF and pancreatic insufficiency, lower MBL-2 protein levels were associated with a steeper rate of decline in lung function and earlier age at first infection with P. aeruginosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/31\">",
"       31",
"      </a>",
"      ]. These effects were exaggerated in individuals who also carried the TGF-beta 1 mutation described above. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=see_link\">",
"       \"Inherited disorders of the complement system\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INCOMPLETE PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 10 percent of patients with suspected CF, the disease manifestations appear to be unusually mild or limited to one organ system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenotypes and genetic causes of patients with this clinical presentation were described in a study of 158 patients who were referred for detailed genotyping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/35\">",
"     35",
"    </a>",
"    ]. Standard genetic testing for CF had been performed on each of these patients prior to inclusion in the study, and this panel had identified either no CFTR mutations or only one mutation. The characteristics of 74 of these patients had been previously published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/36\">",
"     36",
"    </a>",
"    ]. The subjects underwent detailed genetic testing using direct DNA sequencing and structured clinical phenotyping. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On detailed genetic testing, 36 percent of patients proved to have two CFTR mutations, 24 percent had one mutation, and 40 percent did not have any detectable mutations despite exhaustive analysis. It is possible that undetected mutations in the introns, promoters, or regulatory regions of the gene contributed to the phenotypic findings in some of these individuals.",
"     </li>",
"     <li>",
"      Neither sweat chloride concentrations nor pulmonary function tests correlated with the number of CFTR mutations. However, 39 percent of the patients had intermediate sweat chloride concentrations (in the 40 to 60",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      range) and 14 percent had normal sweat chloride concentrations (&lt;40",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Patients with two CFTR mutations were more likely to have absence of the vas deferens and the presence of P. aeruginosa in sputum as compared to those patients with zero CFTR mutations. Patients with zero CFTR mutations frequently presented with steatorrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenetic mechanism responsible for clinical disease without CFTR mutations is unclear. The above findings suggest that factors other than CFTR mutations may lead to disease that is phenotypically similar to CF in some patients. Patients who do not have two CFTR mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have normal or borderline sweat chloride concentrations should be rigorously evaluated for other causes of their symptoms (eg, evaluation for Shwachman-Diamond syndrome in those with pancreatic insufficiency). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DISEASE PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the organ dysfunction seen in CF has been studied in humans and CFTR-knockout mice, but remains incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. It appears that the physical and chemical abnormalities of CF airway secretions result in chronic infection with phenotypically unique bacteria, particularly Pseudomonas species. Other genetic factors, including polymorphisms of the tumor necrosis alpha (TNF-a) gene, may increase susceptibility to P. aeruginosa infection and contribute to the clinical manifestations of CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary abnormalities in fatty acid metabolism have been noted in biopsies of CFTR-expressing tissue from patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/40\">",
"     40",
"    </a>",
"    ]. These changes, which result in increased tissue levels of arachidonic acid, also are present in the mouse model of CF, but are not seen in tissue from patients with inflammatory bowel disease. Thus, increased tissue expression of arachidonic acid and its metabolites may contribute to the abnormal inflammation characteristic of CF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abnormal secretions",
"    </span>",
"    &nbsp;&mdash;&nbsp;CFTR malfunction in the respiratory epithelium is associated with a variety of changes in electrolyte and water transport. The mechanisms involved and ultimate electrolyte composition of airway surface fluid from normal and CF airways is a subject of ongoing research [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/11-13,41-44\">",
"     11-13,41-44",
"    </a>",
"    ]. The net result of these changes is an alteration in the rheology of airway secretions, which become thick and difficult to clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/45\">",
"     45",
"    </a>",
"    ]. An associated finding is an increased concentration of chloride in sweat secretions, which constitutes one of the methods of diagnosis of CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gastrointestinal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thickened secretions caused by CFTR malfunction cause the gastrointestinal complications of CF. Impaired flow of bile and pancreatic secretions cause maldigestion and malabsorption, as well as progressive liver and pancreatic disease, leading to CF-related diabetes. Because of thickened intestinal secretions and maldigestion, CF patients are prone to intestinal obstruction (distal intestinal obstruction syndrome or intussusception) and to rectal prolapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=see_link\">",
"     \"Cystic fibrosis: Overview of gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic lung infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic airway obstruction caused by viscous secretions is followed by progressive pulmonary colonization with pathogenic bacteria, including Haemophilus influenzae, Staphylococcus aureus, and eventually P. aeruginosa",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Burkholderia cepacia complex bacteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link&amp;anchor=H2#H2\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once infection is established, neutrophils are unable to control the bacteria, even though there is massive infiltration of these inflammatory cells into the lung tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/46\">",
"     46",
"    </a>",
"    ]. Recruited neutrophils subsequently release elastase, which overwhelms the antiproteases of the lung and contributes to tissue destruction in a process known as \"prolonged endobronchial protease activity\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, large amounts of DNA and cytosol matrix proteins are released by degranulating neutrophils, contributing to the increased viscosity of the airway mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammation has been noted prior to the development of bacterial colonization, and may be triggered by viral infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/49\">",
"     49",
"    </a>",
"    ]. In turn, chronic infection appears to be the major stimulus for an exuberant but ultimately ineffective inflammatory response that subsequently results in bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The inflammatory response itself appears to contribute to the progression of pulmonary dysfunction; this mechanism is the basis for the use of some anti-inflammatory agents in treating CF lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H11#H11\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Anti-inflammatory therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals with cystic fibrosis are particularly prone to chronic infection with P. aeruginosa, due in part to increased oxygen utilization by epithelial cells, which results in an abnormally decreased oxygen tension within the hyperviscous mucous layer (",
"    <a class=\"graphic graphic_figure graphicRef51872 \" href=\"mobipreview.htm?21/52/22337\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/54\">",
"     54",
"    </a>",
"    ]. This local hypoxia induces the characteristic phenotypic changes in P. aeruginosa (and some other gram negative bacteria), including alginate production and loss of motility. This phenotype is consistent with the development of bacterial macrocolonies (or \"biofilms\") within the hypoxic regions of the airway mucus layer. Once this occurs, eradication of the organism is almost impossible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\", section on 'Persistence of the organism in the airways'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P. aeruginosa also may acquire the ability to persist in the environment of the CF lung. One study found that 36 percent of CF patients were colonized with a hypermutable strain of P. aeruginosa that often persisted for years; such mutator strains were not isolated from patients with acute P. aeruginosa infection who did not have CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequent colonization and persistent infection caused by P. aeruginosa in CF patients is also related to the defective CFTR protein itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/46\">",
"     46",
"    </a>",
"    ]. Normal CFTR protein serves as the receptor for binding of P. aeruginosa lipopolysaccharide (LPS) in vitro, and extracts LPS from the surface of the organism for endocytosis into epithelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/42,56,57\">",
"     42,56,57",
"    </a>",
"    ]. This results in increased intranuclear translocation of the nuclear transcription factor NF kappa B and subsequent immunoactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. This process does",
"    <strong>",
"     not",
"    </strong>",
"    occur in the presence of abnormal CFTR or in CFTR-knockout mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/58\">",
"     58",
"    </a>",
"    ], which may partially explain the inability of CF patients to control these infections. Disease-modifier genes appear to further affect the predisposition to P. aeruginosa infection, as described above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Gene modifiers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis (CF) is caused by mutations in a single large gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Clinical disease requires disease-causing mutations in both copies of the CFTR gene. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phenotypic expression of disease varies widely, as a function of the specific mutations present and the presence of gene modifiers. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic changes in CFTR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations of the CFTR gene have been divided into five different classes (",
"      <a class=\"graphic graphic_figure graphicRef80517 \" href=\"mobipreview.htm?23/6/23663\">",
"       figure 2",
"      </a>",
"      ). In general, mutations in classes I to III cause more severe disease than those in classes IV and V [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39095/abstract/19,25\">",
"       19,25",
"      </a>",
"      ]. However, the clinical implications of a specific combination of mutations are often unclear, and specific mutations should not be used to make assumptions about the severity of disease in an individual patient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic changes in CFTR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A subset of the most frequent CFTR mutations is recommended for initial testing, since the majority of individual mutations are very rare (",
"      <a class=\"graphic graphic_table graphicRef65637 \" href=\"mobipreview.htm?35/38/36459\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic changes in CFTR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common mutation is delta F508 (deletion of three DNA bases coding for the 508th amino acid residue phenylalanine), which is found in approximately 70 percent of Caucasian patients with CF in the United States. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Class II mutations: Defective protein processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gene modifiers are genetic variations that are not directly related to the CFTR gene, but which nonetheless affect the severity or clinical manifestations of disease. Transforming growth factor-beta (TGF-beta) and Mannose-binding lectin are important gene modifiers in CF, and approximately 20 percent of CF patients carry variants in one or both of these genes that may exacerbate the pulmonary disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Gene modifiers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CFTR malfunction is associated with low water content in secretions from the respiratory, pancreatic, and biliary epithelium, which causes the secretions to be viscous and difficult to clear. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Abnormal secretions'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      In the gastrointestinal tract, the abnormal bile and pancreatic secretions cause maldigestion and malabsorption, progressive liver and pancreatic disease, rectal prolapse, and intestinal obstruction (distal intestinal obstruction syndrome or intussusception). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastrointestinal effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the lung, the abnormal secretions cause chronic airway obstruction and reduce bacteriocidal killing, leading to progressive pulmonary colonization with pathogenic bacteria, and to the formation of bacterial biofilms. Chronic infection causes an inflammatory response and tissue destruction, causing bronchiectasis. Infection with P. aeruginosa is particularly favored in patients with CF, due to abnormally decreased oxygen tension within the hyperviscous mucous layer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Chronic lung infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/1\">",
"      Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/2\">",
"      Ratjen F, D&ouml;ring G. Cystic fibrosis. Lancet 2003; 361:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/3\">",
"      Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/4\">",
"      Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/5\">",
"      Drumm ML, Collins FS. Molecular biology of cystic fibrosis. Mol Genet Med 1993; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/6\">",
"      Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/7\">",
"      Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/8\">",
"      Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/9\">",
"      Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992; 68:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/10\">",
"      Guggino WB, Banks-Schlegel SP. Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 2004; 170:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/11\">",
"      Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995; 95:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/12\">",
"      Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/13\">",
"      Goldman MJ, Yang Y, Wilson JM. Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. Nat Genet 1995; 9:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/14\">",
"      Anderson MP, Berger HA, Rich DP, et al. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991; 67:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/15\">",
"      Rich DP, Gregory RJ, Anderson MP, et al. Effect of deleting the R domain on CFTR-generated chloride channels. Science 1991; 253:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/16\">",
"      Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000; 84:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/17\">",
"      Correlation between genotype and phenotype in patients with cystic fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med 1993; 329:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/18\">",
"      de Gracia J, Mata F, Alvarez A, et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005; 60:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/19\">",
"      McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/20\">",
"      Decaestecker K, Decaestecker E, Castellani C, et al. Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients. Eur Respir J 2004; 23:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/21\">",
"      Dugu&eacute;p&eacute;roux I, De Braekeleer M. The CFTR 3849+10kbC-&gt;T and 2789+5G-&gt;A alleles are associated with a mild CF phenotype. Eur Respir J 2005; 25:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/22\">",
"      Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992; 51:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/23\">",
"      Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med 2004; 6:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/24\">",
"      Kerem E. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Pediatr Pulmonol 2005; 40:183.",
"     </a>",
"    </li>",
"    <li>",
"     Moskowitz SM. CFTR-related disorders www.genetests.org (Accessed on February 25, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/26\">",
"      Lukacs GL, Durie PR. Pharmacologic approaches to correcting the basic defect in cystic fibrosis. N Engl J Med 2003; 349:1401.",
"     </a>",
"    </li>",
"    <li>",
"     Fanen P, Hasnain A. Cystic fibrosis and teh CFTR gene. Atlas of Genetic and Cytogenetic Oncology and Hematology, 2001. Available at: file://documents.irevues.inist.fr/bitstream/handle/2042/37827/09-2001-CistFibID30032EL.pdf?sequence=3 (Accessed on February 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/28\">",
"      Antunovic SS, Lukac M, Vujovic D. Longitudinal cystic fibrosis care. Clin Pharmacol Ther 2013; 93:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/29\">",
"      Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol 1996; 22:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/30\">",
"      Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/31\">",
"      Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/32\">",
"      Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/33\">",
"      Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/34\">",
"      Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003; 9:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/35\">",
"      Groman JD, Karczeski B, Sheridan M, et al. Phenotypic and genetic characterization of patients with features of \"nonclassic\" forms of cystic fibrosis. J Pediatr 2005; 146:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/36\">",
"      Groman JD, Meyer ME, Wilmott RW, et al. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med 2002; 347:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/37\">",
"      Kent G, Iles R, Bear CE, et al. Lung disease in mice with cystic fibrosis. J Clin Invest 1997; 100:3060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/38\">",
"      Gosselin D, Stevenson MM, Cowley EA, et al. Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998; 157:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/39\">",
"      Yarden J, Radojkovic D, De Boeck K, et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005; 60:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/40\">",
"      Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004; 350:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/41\">",
"      Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/42\">",
"      Ernst RK, Yi EC, Guo L, et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999; 286:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/43\">",
"      Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/44\">",
"      Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest 2007; 132:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/45\">",
"      Guggino WB. Cystic fibrosis and the salt controversy. Cell 1999; 96:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/46\">",
"      Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012; 18:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/47\">",
"      Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008; 32:783.",
"     </a>",
"    </li>",
"    <li>",
"     Davis PB. Pathophysiology of the lung disease in cystic fibrosis. In: Cystic Fibrosis, Davis PB (Ed), Marcel Dekker, New York 1993. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/49\">",
"      Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/50\">",
"      Heeckeren A, Walenga R, Konstan MW, et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/51\">",
"      DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/52\">",
"      Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/53\">",
"      Wheeler WB, Williams M, Matthews WJ Jr, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr 1984; 104:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/54\">",
"      Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/55\">",
"      Oliver A, Cant&oacute;n R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000; 288:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/56\">",
"      Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/57\">",
"      Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997; 94:12088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39095/abstract/58\">",
"      Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A 2002; 99:6907.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6368 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39095=[""].join("\n");
var outline_f38_11_39095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The normal CFTR gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic changes in CFTR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Class I mutations: Defective protein production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Class II mutations: Defective protein processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Class III mutations: Defective regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Class IV mutations: Defective conduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Class V mutations: Reduced amounts of functional CFTR protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENE MODIFIERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INCOMPLETE PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DISEASE PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abnormal secretions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gastrointestinal effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic lung infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6368|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/43/16063\" title=\"figure 1\">",
"      CFTR gene and CF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/6/23663\" title=\"figure 2\">",
"      Abnormal CFTR function in CF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/52/22337\" title=\"figure 3\">",
"      Pathogenesis pseudomonas in CF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/38/36459\" title=\"table 1\">",
"      Cystic fibrosis screening panel",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32167?source=related_link\">",
"      Cystic fibrosis: Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39096="Bupropion: Pediatric drug information";
var content_f38_11_39096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bupropion: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"    see \"Bupropion: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/7/17526?source=see_link\">",
"    see \"Bupropion: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aplenzin&trade;;",
"     </li>",
"     <li>",
"      Budeprion SR&reg;;",
"     </li>",
"     <li>",
"      Budeprion XL&reg; [DSC];",
"     </li>",
"     <li>",
"      Buproban&reg;;",
"     </li>",
"     <li>",
"      Forfivo&trade; XL;",
"     </li>",
"     <li>",
"      Wellbutrin SR&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin XL&reg;;",
"     </li>",
"     <li>",
"      Wellbutrin&reg;;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ava-Bupropion SR;",
"     </li>",
"     <li>",
"      Bupropion SR&reg;;",
"     </li>",
"     <li>",
"      Novo-Bupropion SR;",
"     </li>",
"     <li>",
"      PMS-Bupropion SR;",
"     </li>",
"     <li>",
"      ratio-Bupropion SR;",
"     </li>",
"     <li>",
"      Sandoz-Bupropion SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; SR;",
"     </li>",
"     <li>",
"      Wellbutrin&reg; XL;",
"     </li>",
"     <li>",
"      Zyban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1002151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Dopamine-Reuptake Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Smoking Cessation Aid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1002188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"      see \"Bupropion: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Safe and effective use in children has not been established; further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents: ADHD: Hydrochloride salt: Immediate release: Some centers use the following doses: Initial: 3 mg/kg/day in 2 divided doses; titrate dose slowly to response (while monitoring for behavioral activation),  up to 6 mg/kg/day in 2 divided doses. Maximum doses studied: Children 20-30 kg: 150 mg/day; 31-40 kg: 200 mg/day; &gt;40 kg: 250 mg/day (Conners, 1996).",
"     <b>",
"      Note:",
"     </b>",
"     Several studies have used target doses ranging from 1.4-6 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents &lt;15 years: Depression, ADHD: Hydrochloride salt: Some centers use the following doses: Initial: 37.5 mg twice daily of immediate release or 50 mg twice daily of sustained release; titrate to response with usual daily dose not to exceed 300 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic studies demonstrate accelerated hepatic metabolism in children and young adolescents, therefore, divided doses are recommended to provide optimal symptom control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;15 years: Depression, ADHD: Hydrochloride salt: Hepatic metabolism is similar to adults; patients may respond well to once daily dosing with sustained release or extended release with maximum daily dose between 300-450 mg/day; see Adult dosing for initial doses and titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;14 years and &ge;40.5 kg: Smoking cessation: Hydrochloride salt:",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists; one adolescent study demonstrated short-term efficacy of 150 mg twice daily of sustained release for 7 weeks with cessation counseling (Muramoto, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: Sustained release: 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should start while the patient is still smoking in order to allow drug to reach steady-state levels prior to smoking cessation; generally, patients should stop smoking during the second week of treatment; treatment should continue for 7-12 weeks; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depression:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Hydrochloride salt: Initial: 100 mg twice daily; increase to recommended dose of 100 mg 3 times/day; maximum dose: 450 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release: Hydrochloride salt: Initial: 150 mg/day given once daily in the morning; may increase to 150 mg twice daily by day 4 if tolerated; target dose: 300 mg/day given as 150 mg twice daily; maximum dose: 400 mg/day given as 200 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Interval between successive doses should be at least 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Hydrochloride salt: Initial: 150 mg/day given once daily in the morning; may increase to the recommended target dose of 300 mg/day given once daily in the morning; this increase may be made as early as day 4 of dosing; if no improvement is observed after several weeks, may increase to maximum dose of  450 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Extended release: Hydrobromide salt: Aplenzin&trade;: Target dose: 348 mg/day administered once daily in the morning. Patients not previously on bupropion: Initial: 174 mg/day in the morning; may increase as early as day 4 of dosing to 348 mg/day; maximum dose: 522 mg/day (if no improvement seen after several weeks on 348 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Switching from bupropion hydrochloride (eg, Wellbutrin immediate release, SR&reg;, XL&reg;) to bupropion hydrobromide (Aplenzin&trade;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 150 mg is equivalent to bupropion hydrobromide 174 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 300 mg is equivalent to bupropion hydrobromide 348 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bupropion hydrochloride 450 mg is equivalent to bupropion hydrobromide 522 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients being treated twice daily or three times daily with bupropion hydrochloride would be switched to the equivalent once daily dose of bupropion hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SAD (Wellbutrin XL&reg;): Initial: 150 mg/day given once daily in the morning; if tolerated, may increase after 1 week to 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Prophylactic treatment should be reserved for those patients with frequent depressive episodes and/or significant impairment. Initiate treatment in the Autumn prior to symptom onset, and discontinue in early Spring with dose tapering to 150 mg/day for 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Smoking cessation (Zyban&reg;): Initial: 150 mg once daily for 3 days; increase to 150 mg twice daily; treatment should start while the patient is still smoking in order to allow drug to reach steady-state levels prior to smoking cessation; generally, patients should stop smoking during the second week of treatment; treatment should continue for 7-12 weeks; maximum dose: 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment/comments in renal impairment:",
"     </b>",
"     Use with caution and consider a reduction in dose and/or dosing frequency; limited pharmacokinetic information suggests elimination of bupropion and/or the active metabolites may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate-to-severe renal impairment: Bupropion exposure was ~twofold higher compared to normal subjects following a 150 mg single dose administration of the sustained release product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     End-stage renal failure: Per the manufacturer, the elimination of hydroxybupropion and threohydrobupropion are reduced in patients with end-stage renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: Use with caution; consider reduced dosage and/or frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic cirrhosis: Use with extreme caution; Adults: Maximum dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Aplenzin&trade;: 174 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Wellbutrin&reg;: 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Wellbutrin SR&reg;: 100 mg/day or 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Wellbutrin XL&reg;: 150 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Zyban&reg;: 150 mg every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 75 mg [generic for Wellbutrin&reg;], 100 mg [generic for Wellbutrin&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin&reg;: 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aplenzin&trade;: 174 mg, 348 mg, 522 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 100 mg [generic for Wellbutrin SR&reg;], 150 mg [generic for Wellbutrin SR&reg;], 150 mg [generic for Wellbutrin XL&reg;], 150 mg [generic for Zyban&reg;], 200 mg [generic for Wellbutrin SR&reg;], 300 mg [generic for Wellbutrin XL&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion SR&reg;: 100 mg [contains tartrazine; generic for Wellbutrin SR&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion SR&reg;: 150 mg [generic for Wellbutrin SR&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Budeprion XL&reg;: 300 mg [DSC] [contains tartrazine; generic for Wellbutrin XL&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Buproban&reg;: 150 mg [generic for Zyban&reg;]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Forfivo&trade; XL: 450 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin XL&reg;: 150 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wellbutrin SR&reg;: 100 mg, 150 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyban&reg;: 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes bupropion hydrobromide tablet, extended release bupropion hydrochloride 450 mg tablet, sustained release hydrochloride tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Aplenzin&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085915.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085915.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Forfivo&trade; XL:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280358.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM280358.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Wellbutrin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089824.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089824.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wellbutrin SR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089826.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wellbutrin XL&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172744.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172744.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Zyban&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089835.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089835.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1002194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals. Do not crush, chew, or divide sustained or extended release tablets; swallow whole. The insoluble shell of the extended-release tablet may remain intact during GI transit and is eliminated in the feces.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1002174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aplenzin&trade;, Wellbutrin XL&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablets: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wellbutrin SR&reg;, Zyban&reg;: Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Dispense in tight, light-resistant container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1002152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorder (FDA approved in adults), seasonal affective disorder (SAD) (FDA approved in adults); adjunct in smoking cessation (FDA approved in adults); also used to treat ADHD in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aplenzin&trade; may be confused with Albenza&reg;, Relenza&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       BuPROPion may be confused with busPIRone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Forfivo&trade; XL may be confused with Forteo&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Wellbutrin XL&reg; may be confused with Wellbutrin SR&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zyban&reg; may be confused with Diovan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F143249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, chest pain, flushing, hyper-/hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, agitation, anxiety, CNS stimulation, confusion, depression, dizziness, fever, headache, hostility, insomnia, irritability, memory decreased, migraine, nervousness, pain, sensory disturbance, sleep disturbance, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, libido decreased, menstrual complaints",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, appetite increased, constipation, diarrhea, dyspepsia, dysphagia, flatulence, nausea, taste perversion, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: UTI, urinary urgency, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Akathisia, arthralgia, arthritis, myalgia, neck pain, paresthesia, tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Auditory disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough increased, pharyngitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (including anaphylaxis, pruritus, urticaria); diaphoresis, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Accommodation abnormality, aggression, akinesia, alopecia, amnesia, anaphylactic shock, anemia, angioedema, aphasia, ataxia, atrioventricular block, bronchospasm, bruxism, colitis, coma, coordination abnormal, cystitis, deafness, delayed hypersensitivity, delirium, delusions, depersonalization, derealization, diplopia, dysarthria, dyskinesia, dyspareunia, dysphoria, dystonia, dysuria, edema, EEG abnormality, emotional lability, erythema multiforme, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal syndrome, extrasystoles, facial edema, gastric reflux, gastrointestinal hemorrhage, glossitis, glycosuria, gum hemorrhage, gynecomastia, hallucinations, hepatic damage, hepatitis, hirsutism, hyper-/hypoglycemia, hyper-/hypokinesia, hypertonia, hypoesthesia, hypomania, impotence, intestinal perforation, intraocular pressure increased, jaundice, leukocytosis, leukopenia, libido increased, liver function abnormal, lymphadenopathy, manic reaction, MI, muscle weakness, musculoskeletal chest pain, mydriasis, myoclonus, neuralgia, neuropathy, orthostatic hypotension, painful erection, pancreatitis, pancytopenia, paranoia, pneumonia, photosensitivity, pulmonary embolism, rhabdomyolysis, salpingitis, sciatica, seizures (dose-related), SIADH, stomach ulcer, Stevens-Johnson syndrome, stomatitis, stroke, suicidal ideation, syncope, tardive dyskinesia, thrombocytopenia, tongue edema, urinary incontinence, urinary retention, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1002157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bupropion or any component; seizure disorder; anorexia/bulimia; use of MAO inhibitors within 14 days; patients undergoing abrupt discontinuation of ethanol or sedatives (including benzodiazepines); patients receiving other dosage forms of bupropion",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4105172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause CNS stimulation (restlessness, anxiety, agitation,  insomnia) or anorexia. Use in patients with depression may be associated with neuropsychiatric symptoms such as delusions, hallucinations, psychosis, confusion, paranoia, and concentrations disturbance. May increase the risks associated with electroconvulsive therapy. Consider discontinuing, when possible, prior to elective surgery. May cause weight loss; use caution in patients where weight loss is not desirable.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with cardiovascular disease, history of hypertension, recent MI, or coronary artery disease; treatment-emergent hypertension (including some severe cases) has been reported, both with bupropion alone and in combination with nicotine transdermal systems. Use with caution and decrease the dose and/or frequency in patients with hepatic or renal dysfunction. May cause motor or cognitive impairment in some patients; use with caution if tasks requiring alertness such as operating machinery or driving are undertaken. May cause allergic reactions; rare cases of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock have been reported. Arthralgia, myalgia, and fever with rash and other symptoms suggestive of delayed hypersensitivity resembling serum sickness may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Extended release tablet: Insoluble tablet shell may remain intact and be visible in the stool.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1002158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bupropion is not FDA approved for use in children. Use in treating psychiatric disorders: Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis in some patients. Bupropion is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use in smoking cessation: Serious neuropsychiatric events, including depression, suicidal thoughts, suicide attempt, and suicide, have been reported with use",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; neuropsychiatric symptoms including psychosis, hallucinations, paranoia, delusions, hostility, agitation, aggression, anxiety, panic, and homicidal ideation have also been reported; some cases may have been complicated by symptoms of nicotine withdrawal following smoking cessation. Smoking cessation (with or without treatment) is associated with nicotine withdrawal symptoms (including depression or agitation), or the exacerbation of underlying psychiatric illness; however, some of the behavioral disturbances reported occurred in treated patients who continued to smoke. These neuropsychiatric symptoms (eg, mood disturbances, psychosis, hostility) have occurred in patients with and without pre-existing psychiatric disease; many cases resolved following therapy discontinuation although in some cases, symptoms persisted. Monitor all patients for behavioral changes and psychiatric symptoms (eg, agitation, depression, suicidal behavior, suicidal ideation); inform patients to discontinue treatment and contact their healthcare provider immediately if they experience any behavioral and/or mood changes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as bupropion, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). This assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bupropion may cause seizures; the risk of seizures is dose-dependent; do not exceed maximum recommended doses; increase dose gradually. Risk of seizures is increased in patients with a history of seizures, anorexia/bulimia, head trauma, CNS tumor, severe hepatic cirrhosis, abrupt discontinuation of sedative-hypnotics or ethanol, and concurrent use of medications which lower seizure threshold (antipsychotics, antidepressants, theophylline, systemic steroids), stimulants, or hypoglycemic agents. Discontinue and do not restart in patients experiencing a seizure. Use with extreme caution in patients at risk for seizures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Budeprion SR&reg; 100 mg and Budeprion XL&reg; 300 mg tablets contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of BuPROPion. Specifically, seizure threshold may be lowered. BuPROPion may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, alcohol tolerance may decrease during treatment. Management: Patients receiving bupropion should be advised to minimize or avoid alcohol consumption due to possible lower alcohol tolerance, and lower seizure threshold associated with heavy alcohol consumption/abrupt discontinuation of heavy consumption.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: BuPROPion may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of BuPROPion. Concentrations of the active metabolite, hydroxybupropion, may also be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: BuPROPion may enhance the serotonergic effect of Lorcaserin. This could result in serotonin syndrome.  Management: Seek alternatives to this combination when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: BuPROPion may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of BuPROPion. Management: Use bupropion with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: BuPROPion may decrease the metabolism of Tricyclic Antidepressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxapine; Protriptyline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5368496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablets:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aplenzin&trade;: Food does not affect peak concentration or time to peak; food increases bioavailability by 19%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wellbutrin XL&reg;: Food does not affect peak concentration or bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained release tablets: Food increases peak concentrations by 11% and AUC by 17% and prolongs the time to peak concentration by 1 hour. These effects are not thought to be clinically significant.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3062314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to adverse events observed in some animal studies, bupropion is classified as pregnancy category C. A significant increase in major teratogenic effects has not been observed following exposure to bupropion during pregnancy; however, the risk of spontaneous abortions may be increased (additional studies are needed to confirm). The long-term effects on development and behavior have not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnancy itself does not provide protection against depression. The ACOG recommends that therapy with antidepressants during pregnancy be individualized and should incorporate the clinical expertise of the mental health clinician, obstetrician, primary care provider, and pediatrician. If treatment is needed, consider gradually stopping antidepressants 10-14 days before the expected date of delivery to prevent potential withdrawal symptoms in the infant. If this is done and the woman is considered to be at risk of relapse from her major depressive disorder, the medication can be restarted following delivery, although the dose should be readjusted to that required before pregnancy. Bupropion has also been evaluated for smoking cessation during pregnancy; current recommendations suggest that pharmacologic treatments be considered only after other therapies have failed. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1002196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, mental status, weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks, tics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ADHD:",
"     </b>",
"     Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1002178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic levels (trough, 12 hours after last dose): 50-100 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1002176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoketone antidepressant structurally different from all other marketed antidepressants; like other antidepressants the mechanism of bupropion's activity is not fully understood. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, and does not inhibit monoamine oxidase or the reuptake of serotonin. Metabolite inhibits the reuptake of norepinephrine. The primary mechanism of action is thought to be dopaminergic and/or noradrenergic.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4105173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Maximum effect: 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1002179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 19-21 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 82% to 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2B6 to  hydroxybupropion; non-CYP-mediated metabolism to  erythrohydrobupropion and threohydrobupropion; these 3 metabolites are active. Preliminary studies suggest hydroxybupropion is 50% and erythrohydrobupropion and threohydrobupropion are 20% as active as parent drug.  Bupropion also undergoes oxidation to form the glycine conjugate of meta-chlorobenzoic acid, the major urinary metabolite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: 21 &plusmn; 9 hours; Metabolites: Hydroxybupropion: 20 &plusmn; 5 hours; Erythrohydrobupropion: 33 &plusmn; 10 hours; Threohydrobupropion: 37 &plusmn; 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Bupropion: Sustained release: &sim;3 hours; extended release: &sim;5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolites: Hydroxybupropion, erythrohydrobupropion, threohydrobupropion: ~7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (87%); feces (10%); only 0.5% of the dose is excreted as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1002199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/7/17526?source=see_link\">",
"      see \"Bupropion: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of bupropion. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Serious neuropsychiatric events, including depression, suicidal thoughts, suicide attempt, and suicide have been reported with use of bupropion for smoking cessation. Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Empty extended release tablets may appear in stool after medication is absorbed (this is normal). Be aware that bupropion is marketed under different names and should not be taken together; Zyban&reg; is for smoking cessation and Wellbutrin&reg; is for treatment of depression.",
"     <b>",
"      Note:",
"     </b>",
"     Excessive use or abrupt discontinuation of alcohol or sedatives may alter seizure threshold.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Depression: Take as directed, in equally divided doses; do not take in larger dose or more often than recommended. Do not discontinue this medicine without consulting prescriber. Do not use alcohol or OTC medications not approved by prescriber. May cause drowsiness, clouded sensorium, headache, restlessness, or agitation (use caution when driving or engaging in tasks requiring alertness or physical coordination until response to drug is known); nausea, vomiting, or dry mouth (small, frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); weight loss; constipation; or impotence (reversible). Report persistent CNS effects (eg, agitation, confusion, anxiety, restlessness, insomnia, psychosis, hallucinations, seizures); suicidal ideation; muscle weakness or tremor; skin rash, hives, itching or irritation; chest pain or palpitations, abdominal pain or blood in stools; yellowing of skin or eyes; or respiratory difficulty, bronchitis, or unusual cough.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Smoking cessation: Use as directed; do not take extra doses. Do not combine nicotine patches with use of Zyban&reg; unless approved by prescriber. May cause dry mouth and insomnia (these may resolve with continued use). Report any respiratory difficulty, unusual cough, dizziness, or muscle tremors.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F5368519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ADHD: Children and Adolescents: Bupropion hydrochloride: Doses ranging from 1.4-5.7 mg/kg/day (mean: 3.3 mg/kg/day) were utilized in 15 ADHD subjects 7-17 years of age (Barrickman, 1995); 72 children with ADHD (6-12 years of age) received 3-6 mg/kg/day (Conners, 1996); adolescents with conduct disorder and substance use disorder were titrated to a maximum fixed daily dose of 300 mg (Riggs, 1998). The immediate-release dosage form was studied in clinical trials for indications other than depression in 104 pediatric patients. This limited exposure does not allow for assessment of the safety and efficacy of bupropion in pediatric patients. Further studies are needed.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrickman LL, Petty PJ, Allen AJ, et al, &ldquo;Bupropion Versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(5):649-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/7775360/pubmed\" id=\"7775360\" target=\"_blank\">",
"        7775360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conners CK, Casat CD, Gualtieri CT, et al, &ldquo;Bupropion Hydrochloride in Attention Deficit Disorder With Hyperactivity,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1996, 35(10):1314-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/8885585/pubmed\" id=\"8885585\" target=\"_blank\">",
"        8885585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson J, &ldquo;Seizures and Bupropion: A Review,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1989, 50(7):256-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/2500425/pubmed\" id=\"2500425\" target=\"_blank\">",
"        2500425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daviss WB, Perel JM, Birmaher B, et al, \"Steady-State Clinical Pharmacokinetics of Bupropion Extended-Release in Youths,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(12):1503-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/17135996/pubmed\" id=\"17135996\" target=\"_blank\">",
"        17135996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J  Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hack S, \"Pediatric Bupropion-Induced Serum Sickness Like Reaction,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(3):478-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/15650506/pubmed\" id=\"15650506\" target=\"_blank\">",
"        15650506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jennison TA, Brown P, Crossett J, et al, &ldquo;A High-Performance Liquid Chromatographic Method for Quantitating Bupropion in Human Plasma or Serum,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1995, 19(2):69-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/7769789/pubmed\" id=\"7769789\" target=\"_blank\">",
"        7769789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kavoussi RJ, Segraves RT, Hughes AR, et al, &ldquo;Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1997, 58(12):532-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/9448656/pubmed\" id=\"9448656\" target=\"_blank\">",
"        9448656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leverich GS, Altshuler LL, Frye MA, et al, &ldquo;Risk of Switch in Mood Polarity to Hypomania or Mania in Patients with Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2006, 163(2):232-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/16449476/pubmed\" id=\"16449476\" target=\"_blank\">",
"        16449476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntyre RS, Mancini DA, McCann S, et al, &ldquo;Topiramate Versus Bupropion SR When Added to Mood Stabilizer Therapy for the Depressive Phase of Bipolar Disorder: A Preliminary Single-Blind Study,&rdquo;",
"      <i>",
"       Bipolar Disord",
"      </i>",
"      , 2002, 4(3):207-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/12180276/pubmed\" id=\"12180276\" target=\"_blank\">",
"        12180276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muramoto ML, Leischow SJ, Sherrill D, et al, \"Randomized, Double-Blind, Placebo-Controlled Ttrial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2007, 161(11):1068-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/17984409/pubmed\" id=\"17984409\" target=\"_blank\">",
"        17984409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka SR, Crismon ML, Hughes CW, et al, \"The Texas Children&rsquo;s Medication Algorithm Project:  Revision of the Algorithm for Pharmacotherapy of ADHD,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(6):642-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/16721314/pubmed\" id=\"16721314\" target=\"_blank\">",
"        16721314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riggs PD, Leon SL, Mikulich SK, et al, &ldquo;An Open Trial of Bupropion for ADHD in Adolescents With Substance Use Disorders and Conduct Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1998, 37(12):1271-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/9847499/pubmed\" id=\"9847499\" target=\"_blank\">",
"        9847499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer T, Biederman J, Kerman K, et al, &ldquo;Desipramine Treatment of Children With Attention-Deficit Hyperactivity Disorder and Tic Disorder or Tourette's Syndrome,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1993, 32(2):354-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/8444765/pubmed\" id=\"8444765\" target=\"_blank\">",
"        8444765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Turpeinen M, Koivuviita N, Tolonen A, et al, \"Effect of Renal Impairment on the Pharmacokinetics of Bupropion and Its Metabolites,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(2):165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/17335546/pubmed\" id=\"17335546\" target=\"_blank\">",
"        17335546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Wyck FJ, Manberg PJ, Miller LL, et al, &ldquo;Overview of Clinically Significant Adverse Reactions to Bupropion,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1983, 44(5 Pt 2):191-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/6406456/pubmed\" id=\"6406456\" target=\"_blank\">",
"        6406456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, Prince JB, Spencer T, et al, &ldquo;An Open Trial of Bupropion for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2003, 54(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/11/39096/abstract-text/12842303/pubmed\" id=\"12842303\" target=\"_blank\">",
"        12842303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12719 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39096=[""].join("\n");
var outline_f38_11_39096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708639\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143210\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143211\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002151\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002188\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143168\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874410\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002194\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002174\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002152\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143252\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143249\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002157\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4105172\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002158\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143235\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5368496\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143179\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062314\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002196\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002178\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002176\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4105173\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002179\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002199\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5368519\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=related_link\">",
"      Bupropion: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/7/17526?source=related_link\">",
"      Bupropion: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39097="Postpartum endometritis";
var content_f38_11_39097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postpartum endometritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Katherine T Chen, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39097/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/11/39097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum endometritis refers to infection of the decidua (ie, pregnancy endometrium). The infection may also extend into the myometrium (called endomyometritis) or involve the parametrium (called parametritis).",
"   </p>",
"   <p>",
"    Postpartum endometritis is a common cause of postpartum febrile morbidity. The United States Joint Commission on Maternal Welfare defines postpartum febrile morbidity as an oral temperature of &ge;38.0 degrees Celsius (100.4 degrees Fahrenheit) on any 2 of the first 10 days postpartum, exclusive of the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/1\">",
"     1",
"    </a>",
"    ]. The first 24 hours are excluded because low grade fever during this period is common and often resolves spontaneously, especially after vaginal birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometritis after a vaginal or cesarean delivery will be discussed here. Endometritis after a miscarriage or abortion, or in women who have not been recently pregnant, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of pregnancy termination\", section on 'Infection/retained products of conception'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=see_link\">",
"     \"Endometritis unrelated to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum endometritis is typically a polymicrobial infection involving a mixture of two to three aerobes and anaerobes from the genital tract. This was illustrated in a study of 55 women with well-defined puerperal endometritis who had endometrial cultures obtained with a triple-lumen catheter to reduce the risk of contamination from organisms on the cervix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/3\">",
"     3",
"    </a>",
"    ]. None of the women had received prophylactic antibiotics. More than one organism was recovered from 70 percent of these women; approximately 60 percent of the isolates were facultative gram positive and gram negative bacteria, approximately 40 percent were anaerobes, and 30 percent were mycoplasmas.",
"   </p>",
"   <p>",
"    Although mycoplasmas are often isolated from the endometrial cavity, antibiotic therapy is not usually required for clinical cure in women who have Ureaplasma urealyticum only, without additional organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Thus, the role of mycoplasmas in the pathogenesis of endometritis is unclear.",
"   </p>",
"   <p>",
"    Sexually transmitted infections, such as Neisseria gonorrhoeae and Chlamydia trachomatis, are uncommon causes of postpartum endometritis, but common causes of endometritis unrelated to pregnancy. Chlamydia trachomatis appears to be more prevalent in patients with late onset of symptoms (two or more weeks after delivery), but data are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In HIV infected women, the microbiology can be broader and include other less likely pathogens, such as herpes simplex virus and cytomegalovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare, but potentially lethal causes of endometritis include clostridium sordellii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], clostridium perfringens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/14\">",
"     14",
"    </a>",
"    ], and streptococcal or staphylococcal toxic shock syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is the most important risk factor for development of postpartum endometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The rates of endometritis after nonelective cesarean, elective cesarean, and vaginal delivery are approximately 30, 7, and less than 3 percent, respectively, in the absence of antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. Nonelective cesarean deliveries are more likely to be associated prolonged rupture of membranes and multiple vaginal exams, and thus subclinical or clinical chorioamnionitis, than elective procedures, which accounts for the high rate of endometritis after nonelective cesarean birth. The risk of endometritis is more than halved when prophylactic antibiotics are administered (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Prevention'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Bacterial vaginosis is an important pathogen in the setting of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/23\">",
"     23",
"    </a>",
"    ]. In a multivariable analysis, the presence of bacterial vaginosis significantly increased the risk of developing postcesarean endometritis (OR 5.8, 95% CI 3.0-10.9) after adjusting for duration of labor, duration of membrane rupture, and maternal age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/24\">",
"     24",
"    </a>",
"    ]. The propensity to upper genital tract infection in women with bacterial vaginosis may be related to higher vaginal concentrations of certain anaerobic and facultative bacteria observed in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=see_link\">",
"     \"Bacterial vaginosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometritis may also occur with chorioamnionitis, but the diagnosis is not made until the patient is postpartum.",
"   </p>",
"   <p>",
"    Additional risk factors for postpartum endometritis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/25-36\">",
"     25-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged labor",
"     </li>",
"     <li>",
"      Prolonged rupture of membranes",
"     </li>",
"     <li>",
"      Multiple cervical examinations",
"     </li>",
"     <li>",
"      Internal fetal or uterine monitoring",
"     </li>",
"     <li>",
"      Large amount of meconium in amniotic fluid",
"     </li>",
"     <li>",
"      Manual removal of the placenta",
"     </li>",
"     <li>",
"      Low socioeconomic status",
"     </li>",
"     <li>",
"      Maternal diabetes mellitus or severe anemia",
"     </li>",
"     <li>",
"      Preterm birth",
"     </li>",
"     <li>",
"      Operative vaginal delivery",
"     </li>",
"     <li>",
"      Postterm pregnancy",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Colonization with group B streptococcus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=see_link&amp;anchor=H8#H8\">",
"       \"Group B streptococcal infection in pregnant women\", section on 'Endometritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nasal carriage of Staphylococcus aureus",
"     </li>",
"     <li>",
"      Heavy vaginal colonization by Streptococcus agalactiae or Escherichia coli",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During labor and delivery, the indigenous cervicovaginal flora enter the uterine cavity, thereby contaminating its contents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The development of infection versus colonization is thought to be related to a complex interaction among host defense mechanisms, the size of the bacterial inoculum, and the virulence of the bacteria involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that a number of the risk factors discussed above serve to facilitate the development of infection. For example, the size of the inoculum is influenced by the length of time in labor, the duration of ruptured membranes, and the number of vaginal examinations and invasive procedures. The potential for infection is enhanced at least 10-fold in cesarean births compared with vaginal births because of the presence of foreign bodies (eg, suture material), myometrial necrosis at the suture line, and formation of hematomas and seromas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologically, the endometrium in endometritis is edematous and hyperemic, with marked inflammatory infiltrates of the endometrial glands, primarily by neutrophils. The inflammatory process may invade the myometrium and parametrium, and there may be areas of necrosis and thrombosis. Pathologically, endometritis can be defined as 5 or more neutrophils per 400 high-power fields in the superficial endometrium and one or more plasma cells per 120 high-power fields in the endometrial stroma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum fever, tachycardia that parallels the rise in temperature, midline lower abdominal pain, and uterine tenderness are the key clinical findings in women with endometritis, and are present in most women. Purulent lochia, chills, headache, malaise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anorexia are additional findings observed in some women.",
"   </p>",
"   <p>",
"    The uterus may be slightly soft and subinvoluted, which can lead to excessive uterine bleeding.",
"   </p>",
"   <p>",
"    The white blood cell count is elevated, but this can be a normal finding in postpartum women secondary to the physiologic leukocytosis of pregnancy and the effects of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A left shift and a rising rather than falling neutrophil count postpartum is suggestive of an infectious process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21703?source=see_link&amp;anchor=H10#H10\">",
"     \"Hematologic changes in pregnancy\", section on 'White blood cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no characteristic sonographic findings associated with postpartum endometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time of onset of signs and symptoms depends upon several factors, including whether intrauterine infection developed antepartum, intrapartum, or postpartum and the bacterium or bacteria causing the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/36\">",
"     36",
"    </a>",
"    ]. For example, group A streptococcus (GAS) infection should be suspected in patients with early onset, high fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116608162\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of postpartum endometritis is clinical and largely based upon the presence of postpartum fever that cannot be attributed to another etiology after a thorough history and physical examination (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The presence of one or more of the clinical findings described above supports the diagnosis, but these findings are nonspecific (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical findings'",
"    </a>",
"    above). In particular, variable degrees of midline abdominal pain and uterine tenderness are common after cesarean delivery, and to a lesser extent after vaginal delivery, in the absence of infection. Some degree of malodorous yellow-red lochia is normal after any delivery.",
"   </p>",
"   <p>",
"    As discussed above, the United States Joint Commission on Maternal Welfare defines postpartum febrile morbidity as an oral temperature of &ge;38.0 degrees Celsius (100.4 degrees Fahrenheit) on any 2 of the first 10 days postpartum, exclusive of the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/1\">",
"     1",
"    </a>",
"    ]. The first 24 hours are excluded because low grade fever during this period is common and often resolves spontaneously, especially after vaginal birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116608421\">",
"    <span class=\"h2\">",
"     Endometritis with toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare, clostridia, streptococci, and staphylococci can lead to endometritis with toxic shock syndrome and other serious complications (eg, necrotizing myometritis, necrotizing fasciitis). This diagnosis is made in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group A streptococcus (GAS) (eg, Streptococcus pyogenes) infection should be suspected in patients with early onset, high fever. High fever with hypotension and involvement of at least two other organ systems (eg, renal, liver, or pulmonary insufficiency; coagulopathy; soft tissue necrosis; erythematous macular rash with desquamation) suggests toxic shock syndrome. With necrotizing myometritis, the uterus may be boggy and nontender due to diminished innervation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staphylococcal toxic shock syndrome is also characterized by fever &gt;38.9&ordm;C, hypotension, diffuse erythroderma, desquamation (unless the patient dies before desquamation can occur), and involvement of at least three organ systems. Onset may be early (within 24 hours of delivery) and difficult to distinguish from GAS toxic shock. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/52/8010?source=see_link\">",
"       \"Staphylococcal toxic shock syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clostridium sordellii has been associated with a distinctive, lethal toxic shock-like syndrome. In one report, affected patients were less than one week postpartum when they had sudden onset of clinical shock: progressive, refractory hypotension was associated with massive and generalized tissue edema, hemoconcentration, a marked leukemoid reaction (total neutrophil count 66,000 to",
"      <span class=\"nowrap\">",
"       93,600/mm3),",
"      </span>",
"      absence of rash or fever, limited or no myonecrosis, and a rapidly lethal course. Clostridium perfringens has been found in necrotizing endomyometritis and fatal toxic shock after medical abortion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=see_link\">",
"       \"Toxic shock syndrome due to Clostridium sordellii\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link\">",
"       \"Clostridial myonecrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with postpartum fever, but no or minimal uterine tenderness or purulent vaginal discharge, other sources of postpartum fever should be considered. Some of these disorders can be diagnosed or excluded by history and physical examination alone; in the remainder, laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging studies will clarify the diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical site infection (cesarean delivery incision, episiotomy incision, perineal lacerations) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"       \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link\">",
"       \"Approach to episiotomy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mastitis or breast abscess (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=see_link\">",
"       \"Common problems of breastfeeding and weaning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/454?source=see_link\">",
"       \"Lactational mastitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=see_link\">",
"       \"Breast abscess\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pyelonephritis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=see_link\">",
"       \"Acute complicated cystitis and pyelonephritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications of anesthesia, such as aspiration pneumonia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Deep vein thrombosis and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"       \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disorders unrelated to pregnancy, such as appendicitis and viral syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31370?source=see_link\">",
"       \"Acute appendicitis in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudomembranous colitis due to Clostridium difficile. This rare, but potentially serious, cause of postpartum fever should be considered in postpartum women who have low-grade fever, abdominal and gastrointestinal symptoms, and recent antibiotic exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link\">",
"       \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ESTABLISHING THE MICROBIOLOGIC CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In uncomplicated infections, it is not important to establish the microbiologic cause since empiric treatment with broad spectrum antibiotic is usually effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116608813\">",
"    <span class=\"h2\">",
"     Endometrial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial cultures are",
"    <strong>",
"     not",
"    </strong>",
"    performed routinely because of the difficulty in obtaining an uncontaminated specimen through the cervix. Furthermore, they yield results too late for clinical use, while rarely changing treatment; thus, they are not cost-effective when performed as a routine procedure in women with postpartum fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15141121\">",
"    <span class=\"h2\">",
"     Cervical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for gonorrhea and chlamydia should be performed if not done previously, if prior results were positive, or if the patient is at high risk of acquiring sexually transmitted infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116608820\">",
"    <span class=\"h2\">",
"     Blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on whether blood cultures should be obtained routinely. Although bacteremia occurs in 5 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/46\">",
"     46",
"    </a>",
"    ], blood cultures are costly, the initial choice of antibiotic therapy has to be made before the results are available, and the results usually do lead to a change in the initial empiric antibiotic regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/47\">",
"     47",
"    </a>",
"    ]. For these reasons, we do not obtain blood cultures in all women with endometritis. However, blood cultures can be useful in guiding antimicrobial treatment if the patient fails to respond to empiric therapy, if the patient is immunocompromised, or if the patient is septic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=see_link\">",
"     \"Blood cultures for the detection of bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, only a single organism may be identified despite polymicrobial endometrial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated for relief of symptoms and to prevent sequelae, such as peritonitis, salpingitis, oophoritis, phlegmon or abscess, and septic pelvic thrombophlebitis. Treatment is the same, regardless of mode of delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19143936\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Drug choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend administration of broad spectrum parenteral antibiotics that include coverage for beta-lactamase producing anaerobes, given the microbiology of these infections (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Microbiology'",
"    </a>",
"    above). Oral antibiotics are an option for mild endometritis diagnosed after the woman has been discharged, especially those post vaginal birth (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Late onset postpartum endometritis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    (900 mg intravenously every eight hours) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is a commonly used, effective regimen: cure rates are 90 to 97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/48-57\">",
"     48-57",
"    </a>",
"    ]. A meta-analysis including 15 randomized trials comparing clindamycin plus an aminoglycoside with other regimens found the risk of treatment failure was higher with the other regimens (RR 1.44, 95% CI 1.15-1.80) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/57\">",
"     57",
"    </a>",
"    ]. Extended interval dosing of gentamicin (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 24 hours) is more convenient and cost-effective and as efficacious and safe as thrice daily dosing (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously every eight hours) for patients with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. Gentamicin levels do not need to be monitored in patients receiving a single daily gentamicin dose. For patients with renal dysfunction, reasonable alternatives to gentamicin include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    (1.5 g every six hours) or clindamycin and a second-generation cephalosporin.",
"   </p>",
"   <p>",
"    Drug treatments reported to be equivalent to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , ceftizoxime,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    with or without tazobactam, and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/3,63-66\">",
"     3,63-66",
"    </a>",
"    ]. However, the trials supporting use of these drugs have been small, thus they may not have been able to determine statistically significant differences in efficacy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    provides good activity against most anaerobes and can be useful with ampicillin and gentamicin, but is not the preferred choice for breastfeeding women if a drug with a better safety profile is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link&amp;anchor=H396541156#H396541156\">",
"     \"Principles of medication use during lactation\", section on 'Metronidazole and tinidazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    among anaerobic bacteria is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/67-69\">",
"     67-69",
"    </a>",
"    ], with widely varying rates of resistance among different geographic regions and institutions. In geographic regions or institutions where there is significant clindamycin resistance in B. fragilis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    (1.5 g every six hours) is a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in invasive group B streptococcus (GBS) isolates ranges from 13 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. For those patients who are known to be colonized with GBS from universal screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/74\">",
"     74",
"    </a>",
"    ], addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    to clindamycin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    regimen or use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We continue treatment until the patient is clinically improved (no fundal tenderness) and afebrile for at least 24 hours. Oral antibiotic therapy after successful parenteral treatment is not required, as randomized trials have shown that it does not improve outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/57,75\">",
"     57,75",
"    </a>",
"    ]. However, if bacteremia was present as indicated by a positive blood culture, we suggest oral antibiotic therapy after discontinuation of parenteral antibiotics to complete a seven-day total course of antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staphylococcal bacteremia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Persistent postpartum fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;A response to the initial antibiotic regimen should be evident within 48 to 72 hours. If the patient has not improved by this time or deteriorated, then further evaluation is indicated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 percent of treatment failures are due to resistant organisms, such as enterococci, which are resistant to cephalosporins or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      . In the absence of information from blood cultures, the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      or penicillin to the regimen can be an effective approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      can be used in penicillin allergic patients.",
"      <br/>",
"      <br/>",
"      Alternatively, the initial antibiotics can be discontinued and ampicillin and sulbactam (eg, Unasyn&reg;) can be initiated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/63,79-81\">",
"       63,79-81",
"      </a>",
"      ]. This regimen is at least as effective as clindamycin plus gentamicin, and is used as first line therapy in some hospitals.",
"      <br/>",
"      <br/>",
"      If blood cultures were performed, treatment decisions are based on drug sensitivity results for any organisms identified. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=see_link\">",
"       \"Treatment of enterococcal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients receiving a thrice daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      regimen, drug levels may not be in the therapeutic range necessitating a change in dose. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=see_link&amp;anchor=H22#H22\">",
"       \"Aminoglycosides\", section on 'Monitoring serum aminoglycoside concentrations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other etiologies of fever should be considered. Sources of persistent fever include an infected hematoma, pelvic cellulitis or abscess, surgical site infection, septic pelvic thrombophlebitis, ovarian vein thrombosis, and myometrial necrosis.",
"      <br/>",
"      <br/>",
"      A complete physical examination should be performed to look for non-uterine sources of infection and worsening pelvic findings (eg, new mass, worsening pain). Targeted imaging studies may be useful to further evaluate suspicious clinical findings or fever refractory to antibiotic therapy. Sonography is useful for visualizing pelvic abscesses and fluid collections (eg, infected hematoma), but insensitive for diagnosis of septic pelvic thrombophlebitis or ovarian vein thrombosis where CT or MRI are more helpful. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=see_link\">",
"       \"Septic pelvic thrombophlebitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"       \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Knowledge of the characteristics of the normal postpartum uterus is useful when the postpartum uterus is imaged during evaluation of postpartum complications as fluid, debris, and gas can be normal findings. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of postpartum care\", section on 'Ultrasound of the involuting uterus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retained products of conception after delivery can cause acute or chronic endometritis related to microbial infection of the necrotic products of conception (eg, fetal membranes, placental fragments), as well as the endometrium. Ultrasound may demonstrate the retained tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/82\">",
"       82",
"      </a>",
"      ]. Diagnosis and treatment are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39384?source=see_link\">",
"       \"Retained products of conception\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Curettage to remove the necrotic material may be necessary to resolve the infection. It is important to not curette the endometrium too vigorously, as this can lead to uterine perforation, adhesion formation and subsequent infertility (ie, Asherman syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/83\">",
"       83",
"      </a>",
"      ]. For this reason, suction curettage is preferable to sharp curettage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"       \"Intrauterine adhesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The possibility of drug fever should be considered in absence of any physical or imaging findings and a pulse rate that does not vary significantly and does not parallel the patient&rsquo;s temperature. Drug fever can be defined as \"a disorder characterized by fever coinciding with the administration of the drug and disappearing after the discontinuation of the drug, when no other cause for the fever is evident after a careful physical examination and laboratory investigation\" (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=see_link\">",
"       \"Drug fever\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19143884\">",
"    <span class=\"h2\">",
"     Relapse or recurrent endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with another episode of endometritis after having been treated for endometritis on initial hospitalization, we suggest change of antibiotics from the initial regimen and further evaluation, as outlined above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Persistent postpartum fever'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Late onset postpartum endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of endometritis develop within the first week after delivery, but 15 percent present between one and six weeks postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/7,84\">",
"     7,84",
"    </a>",
"    ]. Delayed presentation is more common after vaginal than cesarean delivery, and may present as late postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of postpartum hemorrhage\", section on 'Secondary postpartum hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most women with late postpartum endometritis have mild clinical symptoms and signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/7\">",
"     7",
"    </a>",
"    ]. Parenteral treatment is probably not necessary, although the optimum route of drug delivery has not been evaluated in comparative trials. For oral therapy, we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    875 mg by mouth twice a day for seven days to provide coverage of facultative and anaerobic bacteria. We do not consider this drug contraindicated in breastfeeding mothers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3019416\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infections are mild and cured with antibiotic therapy. A systematic review found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and an aminoglycoside combination therapy was successful in resolving symptoms in 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical site infection is a common associated condition when antibiotic therapy is unsuccessful in resolving fever after cesarean delivery, and often requires drainage. Other complications include extension of infection to the peritoneal cavity resulting in peritonitis, intraabdominal abscess, or sepsis. Necrotizing myometritis, necrotizing fasciitis of the abdominal wall, septic pelvic thrombophlebitis, and toxic shock syndrome are rare complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=see_link\">",
"     \"Septic pelvic thrombophlebitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=see_link\">",
"     \"Toxic shock syndrome due to Clostridium sordellii\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/52/8010?source=see_link\">",
"     \"Staphylococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=see_link\">",
"     \"Treatment of streptococcal toxic shock syndrome\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Although there are no data from women with postpartum endometritis, secondary infertility appears to be uncommon with timely diagnosis of endometritis and appropriate treatment in gynecologic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/87\">",
"     87",
"    </a>",
"    ]. Although a severe infection may result in exosalpingitis, endosalpingitis is unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis at cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single dose antibiotic prophylaxis prior to making the skin incision significantly reduces the prevalence of postcesarean delivery endometritis, for both elective and nonelective procedures. The optimum regimen is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=see_link&amp;anchor=H9#H9\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis for vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women undergoing vaginal delivery are not routinely given antibiotic prophylaxis, given their low rate of postpartum endometritis. There are few data from randomized trials regarding the efficacy of antibiotic prophylaxis to prevent endometritis in women at high risk.",
"   </p>",
"   <p>",
"    No randomized trials have evaluated use of prophylactic antibiotics in women who undergo an invasive procedure, such as manual removal of placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A double-blind trial that randomly assigned 424 HIV infected pregnant women anticipating vaginal delivery to receive either a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    (2 g) or placebo intrapartum reported a 53 percent reduction in risk of postpartum endometritis in the cefoxitin group (95% CI 0.24-0.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/89\">",
"     89",
"    </a>",
"    ]. The overall rate of sepsis was similar for both groups",
"    <span class=\"nowrap\">",
"     (40/211",
"    </span>",
"    women [19 percent] in the placebo group and",
"    <span class=\"nowrap\">",
"     36/213",
"    </span>",
"    women [17 percent] in the cefoxitin group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Spontaneous placental extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women undergoing cesarean delivery, four randomized controlled trials with a total of over 2000 subjects reported that spontaneous delivery of the placenta resulted in a significant reduction in postpartum endometritis compared to manual removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Topical antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine antibiotic irrigation may be as effective as intravenous infusion, probably because of absorption of the drug into the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Nevertheless, irrigation has fallen out of favor because it does not appear to offer any advantage over intravenous therapy and may have disadvantages, such as variable absorption.",
"   </p>",
"   <p>",
"    Vaginal lavage with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    during labor has been used to prevent postpartum infection, but a meta-analysis of three randomized trials did not find a statistically significant reduction (RR 0.83, 95% CI 0.61-1.13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal preparation with povidone-iodine prior to cesarean delivery has also been studied as a method to decrease postcesarean endometritis. Available data are inconclusive; one study showed no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/97\">",
"     97",
"    </a>",
"    ], while another showed a significant decrease in endometritis, but no effect on postoperative fever and wound infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39097/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpartum endometritis is a common cause of postpartum febrile morbidity (defined as an oral temperature of 38.0 degrees Celsius [100.4 degrees Fahrenheit] or more on any 2 of the first 10 days postpartum, exclusive of the first 24 hours). The infection begins in the decidua, and then may extend into the myometrial and parametrial tissues. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infection is polymicrobial, usually involving a mixture of two to three aerobes and anaerobes from the lower genital tract. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery is the most important risk factor for development of postpartum endometritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of postpartum endometritis is based upon clinical criteria of fever and uterine tenderness occurring in a postpartum woman. Other signs and symptoms which support the diagnosis include foul lochia, chills, and lower abdominal pain. The uterus may be soft and subinvoluted, which can lead to excessive uterine bleeding. Sepsis is an unusual presentation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Differential diagnosis of postpartum fever includes surgical site infection,",
"      <span class=\"nowrap\">",
"       mastitis/breast",
"      </span>",
"      abscess, urinary tract infection, pneumonia, and pelvic vein thrombosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory studies are of limited value. A rising neutrophil count associated with elevated numbers of bands is suggestive. Endometrial cultures are not useful. Blood cultures can be useful in guiding antimicrobial treatment if the patient fails to respond to empiric therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Establishing the microbiologic cause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of postpartum endometritis is indicated for relief of symptoms and prevention of sequelae. Given the microbiology of these infections, we recommend broad spectrum antibiotics with coverage of beta-lactamase producing anaerobes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (900 mg every eight hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours or 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 24 hours in patients with normal renal function) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (1.5 g every six hours) is a reasonable alternative in areas with significant clindamycin resistance in B. fragilis or if the patient is colonized with group B streptococcus (GBS). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Drug choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We administer parenteral antibiotics until the patient is clinically improved and afebrile for 24 to 48 hours. In the absence of bacteremia, we recommend not prescribing oral antibiotic therapy after successful parenteral treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improvement in symptoms should be evident within 48 to 72 hours of initiating adequate antibiotic therapy. If the patient has not improved by this time, then the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , in penicillin allergic patients, to the regimen can improve the response rate. Further evaluation is indicated. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Persistent postpartum fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing cesarean delivery, we recommend antibiotic prophylaxis and spontaneous, rather than manual, placental extraction to minimize the risk of postpartum endometritis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/1\">",
"      Adair, FL. The American Committee of Maternal Welfare, Inc: Chairman's Address. Am J Obstet Gynecol 1935; 30:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/2\">",
"      Filker R, Monif GR. The significance of temperature during the first 24 hours postpartum. Obstet Gynecol 1979; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/3\">",
"      Rosene K, Eschenbach DA, Tompkins LS, et al. Polymicrobial early postpartum endometritis with facultative and anaerobic bacteria, genital mycoplasmas, and Chlamydia trachomatis: treatment with piperacillin or cefoxitin. J Infect Dis 1986; 153:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/4\">",
"      Watts DH, Eschenbach DA, Kenny GE. Early postpartum endometritis: the role of bacteria, genital mycoplasmas, and Chlamydia trachomatis. Obstet Gynecol 1989; 73:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/5\">",
"      Harrison HR. Prospective studies of Mycoplasma hominis infection in pregnancy. Sex Transm Dis 1983; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/6\">",
"      Patai K, Szil&aacute;gyi G, Hubay M, et al. Severe endometritis caused by genital mycoplasmas after Caesarean section. J Med Microbiol 2005; 54:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/7\">",
"      Hoyme UB, Kiviat N, Eschenbach DA. Microbiology and treatment of late postpartum endometritis. Obstet Gynecol 1986; 68:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/8\">",
"      Ismail MA, Moawad AH, Poon E, Henderson C. Role of Chlamydia trachomatis in postpartum endometritis. J Reprod Med 1987; 32:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/9\">",
"      Giraldo-Isaza MA, Jaspan D, Cohen AW. Postpartum endometritis caused by herpes and cytomegaloviruses. Obstet Gynecol 2011; 117:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/10\">",
"      Hollier LM, Scott LL, Murphree SS, Wendel GD Jr. Postpartum endometritis caused by herpes simplex virus. Obstet Gynecol 1997; 89:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/11\">",
"      R&oslash;rbye C, Petersen IS, Nilas L. Postpartum Clostridium sordellii infection associated with fatal toxic shock syndrome. Acta Obstet Gynecol Scand 2000; 79:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/12\">",
"      Bitti A, Mastrantonio P, Spigaglia P, et al. A fatal postpartum Clostridium sordellii associated toxic shock syndrome. J Clin Pathol 1997; 50:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/13\">",
"      Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006; 43:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/14\">",
"      Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol 2007; 110:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/15\">",
"      Jorup-R&ouml;nstr&ouml;m C, Hofling M, Lundberg C, Holm S. Streptococcal toxic shock syndrome in a postpartum woman. Case report and review of the literature. Infection 1996; 24:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/16\">",
"      Gibney RT, Moore A, Muldowney FP. Toxic-shock syndrome associated with post-partum staphylococcal endometritis. Ir Med J 1983; 76:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/17\">",
"      Gibbs RS, Blanco JD. Streptococcal infections in pregnancy. A study of 48 bacteremias. Am J Obstet Gynecol 1981; 140:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/18\">",
"      Gibbs RS. Infection after cesarean section. Clin Obstet Gynecol 1985; 28:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/19\">",
"      Burrows LJ, Meyn LA, Weber AM. Maternal morbidity associated with vaginal versus cesarean delivery. Obstet Gynecol 2004; 103:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/20\">",
"      Declercq E, Barger M, Cabral HJ, et al. Maternal outcomes associated with planned primary cesarean births compared with planned vaginal births. Obstet Gynecol 2007; 109:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/21\">",
"      Fernandez H, Gagnepain A, Bourget P, et al. Antibiotic prophylaxis against postpartum endometritis after vaginal delivery: a prospective randomized comparison between Amox-CA (Augmentin) and abstention. Eur J Obstet Gynecol Reprod Biol 1993; 50:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/22\">",
"      Smaill F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section. Cochrane Database Syst Rev 2002; :CD000933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/23\">",
"      Soper DE. Bacterial vaginosis and postoperative infections. Am J Obstet Gynecol 1993; 169:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/24\">",
"      Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol 1990; 75:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/25\">",
"      D'Angelo LJ, Sokol RJ. Time-related peripartum determinants of postpartum morbidity. Obstet Gynecol 1980; 55:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/26\">",
"      Bobitt JR, Ledger WJ. Amniotic fluid analysis. Its role in maternal neonatal infection. Obstet Gynecol 1978; 51:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/27\">",
"      Diamond MP, Entman SS, Salyer SL, et al. Increased risk of endometritis and wound infection after cesarean section in insulin-dependent diabetic women. Am J Obstet Gynecol 1986; 155:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/28\">",
"      Jazayeri A, Jazayeri MK, Sahinler M, Sincich T. Is meconium passage a risk factor for maternal infection in term pregnancies? Obstet Gynecol 2002; 99:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/29\">",
"      Tran SH, Caughey AB, Musci TJ. Meconium-stained amniotic fluid is associated with puerperal infections. Am J Obstet Gynecol 2003; 189:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/30\">",
"      Wilkinson C, Enkin MW. Manual removal of placenta at caesarean section. Cochrane Database Syst Rev 2000; :CD000130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/31\">",
"      Ely JW, Rijhsinghani A, Bowdler NC, Dawson JD. The association between manual removal of the placenta and postpartum endometritis following vaginal delivery. Obstet Gynecol 1995; 86:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/32\">",
"      Chaim W, Bashiri A, Bar-David J, et al. Prevalence and clinical significance of postpartum endometritis and wound infection. Infect Dis Obstet Gynecol 2000; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/33\">",
"      Caughey AB, Musci TJ. Complications of term pregnancies beyond 37 weeks of gestation. Obstet Gynecol 2004; 103:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/34\">",
"      Louis J, Buhari MA, Allen D, et al. Postpartum morbidity associated with advanced HIV disease. Infect Dis Obstet Gynecol 2006; 2006:79512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/35\">",
"      Bj&ouml;rklund K, Mutyaba T, Nabunya E, Mirembe F. Incidence of postcesarean infections in relation to HIV status in a setting with limited resources. Acta Obstet Gynecol Scand 2005; 84:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/36\">",
"      Faro S. Postpartum endometritis. Clin Perinatol 2005; 32:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/37\">",
"      Newton ER, Prihoda TJ, Gibbs RS. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol 1990; 75:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/38\">",
"      Spore WW, Moskal PA, Nakamura RM, Mishell DR Jr. Bacteriology of postpartum oviducts and endometrium. Am J Obstet Gynecol 1970; 107:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/39\">",
"      Casey BM, Cox SM. Chorioamnionitis and endometritis. Infect Dis Clin North Am 1997; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/40\">",
"      Acker DB, Johnson MP, Sachs BP, Friedman EA. The leukocyte count in labor. Am J Obstet Gynecol 1985; 153:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/41\">",
"      Hartmann KE, Barrett KE, Reid VC, et al. Clinical usefulness of white blood cell count after cesarean delivery. Obstet Gynecol 2000; 96:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/42\">",
"      Mulic-Lutvica A, Axelsson O. Postpartum ultrasound in women with postpartum endometritis, after cesarean section and after manual evacuation of the placenta. Acta Obstet Gynecol Scand 2007; 86:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/43\">",
"      Lurie S, Vaknine H, Izakson A, et al. Group A Streptococcus causing a life-threatening postpartum necrotizing myometritis: a case report. J Obstet Gynaecol Res 2008; 34:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/44\">",
"      de Moya MA, del Carmen MG, Allain RM, et al. Case records of the Massachusetts General Hospital. Case 33-2009. A 35-year-old woman with fever, abdominal pain, and hypotension after cesarean section. N Engl J Med 2009; 361:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/45\">",
"      Ghai S, Ghai V, Sunderji S. Fulminant postcesarean Clostridium difficile pseudomembranous colitis. Obstet Gynecol 2007; 109:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/46\">",
"      Kankuri E, Kurki T, Carlson P, Hiilesmaa V. Incidence, treatment and outcome of peripartum sepsis. Acta Obstet Gynecol Scand 2003; 82:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/47\">",
"      Locksmith GJ, Duff P. Assessment of the value of routine blood cultures in the evaluation and treatment of patients with chorioamnionitis. Infect Dis Obstet Gynecol 1994; 2:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/48\">",
"      diZerega G, Yonekura L, Roy S, et al. A comparison of clindamycin-gentamicin and penicillin-gentamicin in the treatment of post-cesarean section endomyometritis. Am J Obstet Gynecol 1979; 134:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/49\">",
"      Faro S, Phillips LE, Baker JL, et al. Comparative efficacy and safety of mezlocillin, cefoxitin, and clindamycin plus gentamicin in postpartum endometritis. Obstet Gynecol 1987; 69:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/50\">",
"      Alvarez RD, Kilgore LC, Huddleston JF. A comparison of mezlocillin versus clindamycin/gentamicin for the treatment of postcesarean endomyometritis. Am J Obstet Gynecol 1988; 158:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/51\">",
"      Faro S, Martens M, Hammill H, et al. Ticarcillin/clavulanic acid versus clindamycin and gentamicin in the treatment of post-cesarean endometritis following antibiotic prophylaxis. Obstet Gynecol 1989; 73:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/52\">",
"      Gibbs RS, Blanco JD, Castaneda YS, St Clair PJ. A double-blind, randomized comparison of clindamycin-gentamicin versus cefamandole for treatment of post-cesarean section endomyometritis. Am J Obstet Gynecol 1982; 144:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/53\">",
"      Gibbs RS, Blanco JD, Duff P, et al. A double-blind, randomized comparison of moxalactam versus clindamycin-gentamicin in treatment of endomyometritis after cesarean section delivery. Am J Obstet Gynecol 1983; 146:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/54\">",
"      Gilstrap LC 3rd, Maier RC, Gibbs RS, et al. Piperacillin versus clindamycin plus gentamicin for pelvic infections. Obstet Gynecol 1984; 64:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/55\">",
"      Herman G, Cohen AW, Talbot GH, et al. Cefoxitin versus clindamycin and gentamicin in the treatment of postcesarean section infections. Obstet Gynecol 1986; 67:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/56\">",
"      Sweet RL, Roy S, Faro S, et al. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstet Gynecol 1994; 83:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/57\">",
"      French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev 2004; :CD001067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/58\">",
"      Mitra AG, Whitten MK, Laurent SL, Anderson WE. A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection. Am J Obstet Gynecol 1997; 177:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/59\">",
"      Del Priore G, Jackson-Stone M, Shim EK, et al. A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis. Obstet Gynecol 1996; 87:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/60\">",
"      Livingston JC, Llata E, Rinehart E, et al. Gentamicin and clindamycin therapy in postpartum endometritis: the efficacy of daily dosing versus dosing every 8 hours. Am J Obstet Gynecol 2003; 188:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/61\">",
"      Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/62\">",
"      Sunyecz JA, Wiesenfeld HC, Heine RP. The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis. Infect Dis Obstet Gynecol 1998; 6:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/63\">",
"      Stovall TG, Thorpe EM Jr, Ling FW. Treatment of post-cesarean section endometritis with ampicillin and sulbactam or clindamycin and gentamicin. J Reprod Med 1993; 38:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/64\">",
"      MacGregor RR, Graziani AL, Samuels P. Randomized, double-blind study of cefotetan and cefoxitin in post-cesarean section endometritis. Am J Obstet Gynecol 1992; 167:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/65\">",
"      Soper DE, Brockwell NJ, Dalton HP. The importance of wound infection in antibiotic failures in the therapy of postpartum endometritis. Surg Gynecol Obstet 1992; 174:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/66\">",
"      Figueroa-Damian R, Villagrana-Zesati R, San Mart&iacute;n-Herrasti JM, Arredondo-Garcia JL. [Comparison of the therapeutic efficacy of the piperacillin/tazobactame combination vs. ampicillin and gentamycin in in the management of post-cesarean endometritis]. Ginecol Obstet Mex 1996; 64:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/67\">",
"      Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004; 39:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/68\">",
"      Jamal W, Shahin M, Rotimi VO. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007. Anaerobe 2010; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/69\">",
"      Goldstein EJ, Citron DM. Activity of a novel carbapenem, doripenem, against anaerobic pathogens. Diagn Microbiol Infect Dis 2009; 63:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/70\">",
"      McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/71\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/72\">",
"      Borchardt SM, DeBusscher JH, Tallman PA, et al. Frequency of antimicrobial resistance among invasive and colonizing Group B streptococcal isolates. BMC Infect Dis 2006; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/73\">",
"      Castor ML, Whitney CG, Como-Sabetti K, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008; 2008:727505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/74\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/75\">",
"      Dinsmoor MJ, Newton ER, Gibbs RS. A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis. Obstet Gynecol 1991; 77:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/76\">",
"      Duff P. Antibiotic selection in obstetrics: making cost-effective choices. Clin Obstet Gynecol 2002; 45:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/77\">",
"      Walmer D, Walmer KR, Gibbs RS. Enterococci in post-cesarean endometritis. Obstet Gynecol 1988; 71:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/78\">",
"      Brumfield CG, Hauth JC, Andrews WW. Puerperal infection after cesarean delivery: evaluation of a standardized protocol. Am J Obstet Gynecol 2000; 182:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/79\">",
"      Gall S, Koukol DH. Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. J Reprod Med 1996; 41:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/80\">",
"      Rijhsinghani A, Savopoulos SE, Walters JK, et al. Ampicillin/sulbactam versus ampicillin alone for cesarean section prophylaxis: a randomized double-blind trial. Am J Perinatol 1995; 12:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/81\">",
"      Resnik E, Harger JH, Kuller JA. Early postpartum endometritis. Randomized comparison of ampicillin/sulbactam vs. ampicillin, gentamicin and clindamycin. J Reprod Med 1994; 39:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/82\">",
"      Zuckerman J, Levine D, McNicholas MM, et al. Imaging of pelvic postpartum complications. AJR Am J Roentgenol 1997; 168:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/83\">",
"      Klein SM, Garc&iacute;a CR. Asherman's syndrome: a critique and current review. Fertil Steril 1973; 24:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/84\">",
"      Gibbs RS, Rodgers PJ, Castaneda YS, Ramzy I. Endometritis following vaginal delivery. Obstet Gynecol 1980; 56:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/85\">",
"      Khong TY, Khong TK. Delayed postpartum hemorrhage: a morphologic study of causes and their relation to other pregnancy disorders. Obstet Gynecol 1993; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/86\">",
"      Atterbury JL, Groome LJ, Baker SL, et al. Hospital readmission for postpartum endometritis. J Matern Fetal Med 1998; 7:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/87\">",
"      Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/88\">",
"      Chongsomchai C, Lumbiganon P, Laopaiboon M. Prophylactic antibiotics for manual removal of retained placenta in vaginal birth. Cochrane Database Syst Rev 2006; :CD004904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/89\">",
"      Sebitloane HM, Moodley J, Esterhuizen TM. Prophylactic antibiotics for the prevention of postpartum infectious morbidity in women infected with human immunodeficiency virus: a randomized controlled trial. Am J Obstet Gynecol 2008; 198:189.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/90\">",
"      Atkinson MW, Owen J, Wren A, Hauth JC. The effect of manual removal of the placenta on post-cesarean endometritis. Obstet Gynecol 1996; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/91\">",
"      Lasley DS, Eblen A, Yancey MK, Duff P. The effect of placental removal method on the incidence of postcesarean infections. Am J Obstet Gynecol 1997; 176:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/92\">",
"      Dehbashi S, Honarvar M, Fardi FH. Manual removal or spontaneous placental delivery and postcesarean endometritis and bleeding. Int J Gynaecol Obstet 2004; 86:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/93\">",
"      Baksu A, Kalan A, Ozkan A, et al. The effect of placental removal method and site of uterine repair on postcesarean endometritis and operative blood loss. Acta Obstet Gynecol Scand 2005; 84:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/94\">",
"      Elliott JP, Flaherty JF. Comparison of lavage or intravenous antibiotics at cesarean section. Obstet Gynecol 1986; 67:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/95\">",
"      Berkeley AS, Hirsch JC, Freedman KS, Ledger WJ. Cefotaxime for cesarean section prophylaxis in labor. Intravenous administration vs. lavage. J Reprod Med 1990; 35:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/96\">",
"      Lumbiganon P, Thinkhamrop J, Thinkhamrop B, Tolosa JE. Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV). Cochrane Database Syst Rev 2004; :CD004070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/97\">",
"      Reid VC, Hartmann KE, MCMahon M, Fry EP. Vaginal preparation with povidone iodine and postcesarean infectious morbidity: a randomized controlled trial. Obstet Gynecol 2001; 97:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39097/abstract/98\">",
"      Starr RV, Zurawski J, Ismail M. Preoperative vaginal preparation with povidone-iodine and the risk of postcesarean endometritis. Obstet Gynecol 2005; 105:1024.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5488 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39097=[""].join("\n");
var outline_f38_11_39097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116608162\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116608421\">",
"      Endometritis with toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ESTABLISHING THE MICROBIOLOGIC CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116608813\">",
"      Endometrial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15141121\">",
"      Cervical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116608820\">",
"      Blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19143936\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Drug choice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Persistent postpartum fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19143884\">",
"      Relapse or recurrent endometritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Late onset postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3019416\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic prophylaxis at cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antibiotic prophylaxis for vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Spontaneous placental extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Topical antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31370?source=related_link\">",
"      Acute appendicitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/10999?source=related_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30602?source=related_link\">",
"      Bacterial vaginosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21703?source=related_link\">",
"      Hematologic changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/454?source=related_link\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39384?source=related_link\">",
"      Retained products of conception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/41/6807?source=related_link\">",
"      Septic pelvic thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=related_link\">",
"      Toxic shock syndrome due to Clostridium sordellii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8519?source=related_link\">",
"      Treatment of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39098="General principles of management of rheumatoid arthritis in adults";
var content_f38_11_39098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of management of rheumatoid arthritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Larry W Moreland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/11/39098/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/11/39098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rheumatoid arthritis (RA) is directed toward the control of synovitis and the prevention of joint injury. The choice of therapies depends upon several factors, including the severity of disease activity when therapy is initiated and the response of the patient to prior therapeutic interventions.",
"   </p>",
"   <p>",
"    Common principles that guide management strategies and the choice of agents have been derived from an increased understanding of the disease and from evidence from clinical trials and other studies. These strategies include approaches directed at achieving remission or low disease activity by more rapid and sustained control of inflammation and by the institution of disease-modifying antirheumatic drug (DMARD) therapy early in the disease course.",
"   </p>",
"   <p>",
"    The general principles and treatment strategies that should be applied to the management of RA are reviewed here. The initial therapy of RA and the treatment of patients resistant to initial disease-modifying antirheumatic drugs are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6421551\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our overall approach to the treatment of patients with rheumatoid arthritis (RA) depends upon the timely and judicious use of several types of therapeutic interventions. The appropriate use of these therapies is based upon an understanding of a group of general principles that have been widely accepted by major working groups and by professional organizations of rheumatologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H169761721\">",
"     'Recommendations by major groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These principles include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early recognition and diagnosis (see",
"      <a class=\"local\" href=\"#H2703960\">",
"       'Early recognition and diagnosis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Care by an expert in the treatment of rheumatic diseases, such as a rheumatologist (see",
"      <a class=\"local\" href=\"#H2704646\">",
"       'Care by a rheumatologist'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Early use of DMARDs for all patients diagnosed with RA (see",
"      <a class=\"local\" href=\"#H111269724\">",
"       'Early use of DMARDs'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Importance of tight control with target of remission or low disease activity (see",
"      <a class=\"local\" href=\"#H6422708\">",
"       'Tight control'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Use of antiinflammatory agents, including nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids, only as adjuncts to therapy (see",
"      <a class=\"local\" href=\"#H169759626\">",
"       'Adjunctive role of antiinflammatory agents'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The application of these principles has resulted in significant improvement in the outcomes of treatment, although the etiology and pathogenesis of RA are complex and are not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Such improvements may owe even more to the therapeutic strategies that have been adopted than to the development and use of newer and more potent drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RA is characterized by acute and chronic inflammation in the synovium, which is associated with a proliferative and destructive process in joint tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. Many elements of innate and adaptive immunity are involved in this process, and evidence of significant and irreversible joint injury may occur as early as during the first two years of disease if inflammation persists. Measures aimed at identifying early active disease and at markedly reducing inflammation are, therefore, essential for modifying disease outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/6,8,11,12\">",
"     6,8,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6422708\">",
"     'Tight control'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2703960\">",
"    <span class=\"h2\">",
"     Early recognition and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving the benefits of early intervention with disease-modifying antirheumatic drugs (DMARDs) depends upon making the diagnosis of RA as early as possible. The recognition of RA early in the course of inflammatory arthritis, before irreversible injury has occurred, is thus an important element of effective management. (See",
"    <a class=\"local\" href=\"#H111269724\">",
"     'Early use of DMARDs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    International collaborative efforts led in 2010 to the development of new classification criteria for RA, which have identified factors that support the early diagnosis of RA among patients presenting with inflammatory arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/13\">",
"     13",
"    </a>",
"    ]. These criteria are directed at the recognition of patients with early arthritis who are most likely to develop progressive and erosive disease. The diagnosis and differential diagnosis of RA are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18521?source=see_link\">",
"     \"Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2704646\">",
"    <span class=\"h2\">",
"     Care by a rheumatologist",
"    </span>",
"    &nbsp;&mdash;&nbsp;An expert in the treatment of rheumatic diseases, such as a rheumatologist, should participate in the care of patients with inflammatory arthritis who are suspected of having RA and in the ongoing care of patients diagnosed with this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. The early and ongoing care of patients with RA by a rheumatologist is associated with better disease outcomes compared with care rendered primarily by other clinicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/15-19\">",
"     15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in one study of 598 patients from an early arthritis cohort (symptoms for less than two years), those in whom assessment by a rheumatologist had been delayed at least 12 weeks from symptom onset, compared with those evaluated within less than 12 weeks, were significantly more likely not to achieve DMARD-free remission (hazard ratio 1.87, 95% CI 1.18-2.99) and had a significantly higher rate of joint destruction (calculated as 1.34-fold greater) over six years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial rheumatology consultation allows the diagnosis to be made or reassessed, the severity of disease to be estimated, and a plan of care to be developed and initiated. The frequency of subsequent specialist care depends upon the severity of symptoms and joint inflammation, upon the patient&rsquo;s response to treatment, upon the complexity and risks associated with the therapy, and upon the preferences of the patient and primary care physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111269512\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonpharmacologic measures and other medical interventions are important in the comprehensive management of RA in all stages of disease, in addition to antiinflammatory and antirheumatic drug therapies. Patient education that addresses issues related to the disease and its management is indicated for all patients with RA. Attention to health promotion and specific strategies aimed at minimizing the adverse effects of RA and of agents used to treat it are also appropriate. These therapies are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Briefly, these measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient education",
"     </li>",
"     <li>",
"      Psychosocial interventions",
"     </li>",
"     <li>",
"      Rest, exercise, and physical and occupational therapy",
"     </li>",
"     <li>",
"      Nutritional and dietary counseling",
"     </li>",
"     <li>",
"      Interventions to reduce risks of cardiovascular disease, including smoking cessation, and of osteoporosis",
"     </li>",
"     <li>",
"      Immunizations to decrease risk of infectious complications of immunosuppressive therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13780804\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111270327\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to starting, resuming, or significantly increasing therapy with nonbiologic or biologic DMARDs, we do the following baseline studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General testing for all patients &mdash; We obtain a baseline complete blood count, serum creatinine, aminotransferases, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in all patients.",
"     </li>",
"     <li>",
"      Serologic testing for hepatitis prior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or biologic DMARDs &mdash; All patients at increased risk of hepatitis, such as those who have a history of intravenous drug abuse, those who have had multiple sex partners in the previous six months, and those who are healthcare workers, should be screened for hepatitis B and C before starting these medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1\">",
"       1",
"      </a>",
"      ]. Some experts, including the authors, prefer to screen for hepatitis B and C in all patients without a known history of hepatitis before initiating therapy with these medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ophthalmologic screening for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      use &mdash; A complete baseline ophthalmologic examination should be performed within the first year of treatment, including examination of the retina through a dilated pupil and automated visual field testing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H16#H16\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Monitoring for toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for latent tuberculosis &mdash; We screen for latent tuberculosis (TB), consistent with the US Centers for Disease Control (CDC) and 2008 American College of Rheumatology (ACR) guidelines, with skin testing or an interferon-gamma release assay prior to all biologic DMARDs and prior to use of the Janus kinase inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      ; such screening is based upon evidence that these medications, including the tumor necrosis factor (TNF) inhibitors, other biologics, and tofacitinib, may increase the risk of mycobacterial infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1,21,22\">",
"       1,21,22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We also screen for latent TB in patients about to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX), but some experts do not perform testing in such patients, given the lack of sufficient evidence to document the benefit of this approach. A possible exception is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , since there is no clear evidence of an increased risk of TB with this agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/23\">",
"       23",
"      </a>",
"      ]. We obtain a chest radiograph in patients with a history of other risk factors for latent TB, even if screening tests are negative, given the risks of false-negative testing. Additionally, skin testing should be repeated in patients with new TB exposures. Glucocorticoids and other factors may cause false-negative results. Screening for latent TB is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Interferon-gamma release assays can be used in place of tuberculin skin testing in the United States, according to CDC recommendations, and may be preferred in patients who have previously received vaccination with Bacillus Calmette-Guerin (BCG). However, in some countries, tuberculin skin testing is preferred. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169758115\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choices between treatment options are based upon multiple factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of disease activity (eg, mild versus moderate to severe)",
"     </li>",
"     <li>",
"      Stage of therapy (eg, initial versus subsequent therapy in patients resistant to a given intervention)",
"     </li>",
"     <li>",
"      Regulatory restrictions (eg, governmental or health insurance company coverage limitations)",
"     </li>",
"     <li>",
"      Patient preferences (eg, route and frequency of drug administration, monitoring requirements, personal cost)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use a combination of the following types of therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidly acting antiinflammatory medications, including nonsteroidal antiinflammatory drugs (NSAIDs) and systemic and intraarticular glucocorticoids (see",
"      <a class=\"local\" href=\"#H169759626\">",
"       'Adjunctive role of antiinflammatory agents'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Disease-modifying antirheumatic drugs (DMARDs), including nonbiologic (traditional small molecule or synthetic) and biologic DMARDs, and an orally administered small molecule kinase inhibitor, which all have the potential to reduce or prevent joint damage and to preserve joint integrity and function (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33382?source=see_link\">",
"       \"Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases\"",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      The nonbiologic DMARDs most frequently used include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33382?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases\", section on 'Disease-modifying antirheumatic drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=see_link\">",
"       \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"       \"Leflunomide in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Biologic DMARDs, produced by recombinant DNA technology, generally target cytokines or their receptors or are directed against other cell surface molecules. These include anticytokine therapies, such as the tumor necrosis factor (TNF)-alpha inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"       golimumab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      ; the interleukin (IL)-1 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ; and the IL-6 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      . They also include other biologic response modifiers such as the T-cell costimulation blocker,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      (CTLA4-Ig), and the anti-CD20 B-cell depleting monoclonal antibody,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"       \"Overview of biologic agents in the rheumatic diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"       \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"       \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"       \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Several kinase inhibitors are in development for use in RA, and one of these,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      , is available for such clinical use in the United States and is under review for potential approval in Europe. Tofacitinib is an orally administered small molecule DMARD that inhibits cytokine and growth factor signalling through interference with Janus kinases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=see_link&amp;anchor=H5878192#H5878192\">",
"       \"Cytokine networks in rheumatic diseases: Implications for therapy\", section on 'JAK inhibition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111269724\">",
"    <span class=\"h2\">",
"     Early use of DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that all patients diagnosed with RA be started on disease-modifying antirheumatic drug (DMARD) therapy as soon as possible. The choice of initial drug therapy depends in large part upon the degree of disease activity. We distinguish between those patients with mildly active disease and the majority of patients with more active disease. Our choice of drug therapies in patients with RA and the evidence supporting these choices is described in detail separately. Briefly, we take the following approach (see",
"    <a class=\"local\" href=\"#H344392649\">",
"     'Assessment of disease activity'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mildly active RA, we initiate antiinflammatory therapy with a NSAID for rapid symptomatic relief and begin DMARD treatment with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with moderately to severely active RA, we initiate antiinflammatory therapy with either a NSAID or glucocorticoid, depending upon the degree of disease activity, and generally start DMARD therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients resistant to initial DMARD therapy (eg, MTX), we treat with a combination of DMARDs (eg, MTX plus either a TNF inhibitor or SSZ and HCQ) or, alternatively, we switch the patient to a different DMARD of potentially comparable efficacy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      or a TNF inhibitor), while also treating the active inflammation with antiinflammatory drug therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"       \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of the joint damage that ultimately results in disability begins early in the course of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As an example, more than 80 percent of patients with RA of less than two years&rsquo; duration had joint space narrowing on plain radiographs of the hands and wrists, while two-thirds had erosions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/25\">",
"     25",
"    </a>",
"    ]. The use of more sensitive imaging techniques, such as magnetic resonance imaging (MRI) and high resolution ultrasonography, can identify even earlier damage than that which is recognized by radiography, although the prognostic implications of such findings are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Better outcomes are achieved by early compared with delayed intervention with DMARDs in patients with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/11,29-33\">",
"     11,29-33",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 1435 patients involved in 14 trials, primarily of MTX or other nonbiologic DMARDs, found a progressive decrease over time in the likelihood of a significant response to DMARD therapy. Response rates were higher in patients with no more than one year of disease than in those with one to two years of disease, and response rates were lowest in the group with greater than 10 years of disease (53 versus 43 versus 35 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A further observational study comparing very early (median disease duration of three months) with late early (median disease duration of 12 months) initiation of nonbiologic (traditional) DMARD therapy showed significantly greater improvement in disease activity in the very early group within three months after starting DMARDs; the greater degree of improvement in the very early treatment group remained statistically and clinically significant after 36 weeks of DMARD therapy (Disease Activity Score for 28 joints [DAS28] improvement of 2.8 versus 1.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found that the combination of MTX with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      was more effective upon evaluation after one year of treatment in patients begun on therapy less than four months after diagnosis compared with those begun on therapy from four months to two years after diagnosis (DAS28 remission rates of 70 versus 48 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111270903\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be seen on a regular basis for clinical evaluation and monitoring of clinical and laboratory assessment of disease activity and for screening for drug toxicities. The initial evaluation and subsequent monitoring should also include periodic assessment of disease activity using a quantitative composite measure of disease activity. (See",
"    <a class=\"local\" href=\"#H344392649\">",
"     'Assessment of disease activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, the ongoing evaluation and monitoring of patients with RA following the initiation of therapy also involves:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient and clinician assessment of symptoms and functional status (see",
"      <a class=\"local\" href=\"#H111271321\">",
"       'Symptoms and functional status'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Evaluation of joint involvement and extraarticular manifestations (see",
"      <a class=\"local\" href=\"#H111271346\">",
"       'Physical examination'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Laboratory markers (see",
"      <a class=\"local\" href=\"#H111271371\">",
"       'Laboratory monitoring of disease activity'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H111271411\">",
"       'Monitoring and prevention of drug toxicity'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Imaging (see",
"      <a class=\"local\" href=\"#H111271451\">",
"       'Imaging'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344392649\">",
"    <span class=\"h2\">",
"     Assessment of disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity should be evaluated initially and at all subsequent visits. We recommend that a structured assessment of disease activity using a composite measure, such as those described here, should be performed initially, and most patients should be seen at least every three months to monitor the response to therapy using the same measure. Adjustments to treatment regimens should be made to quickly achieve and maintain control of disease activity if targeted treatment goals (remission or low disease activity), rather than an undefined degree of improvement, have not been achieved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361032#H7361032\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Composite indices for disease activity assessment'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6422708\">",
"     'Tight control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial assessment, made once the diagnosis is established, helps to distinguish the smaller group of patients who present with mild disease from the majority of patients who present with moderately to severely active disease and who are usually treated initially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of periodic structured assessments of disease activity is complementary to ongoing regular monitoring of disease manifestations, disease progression, joint injury, disability, and complications of the disease and to monitoring for adverse effects of medications. (See",
"    <a class=\"local\" href=\"#H111270903\">",
"     'Assessment and monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Multiple composite measures employing different combinations and weighting of these variables have been developed for use in clinical research and practice. Among the greater than 60 activity measures available for evaluation of patients with RA, the six measures noted below have been identified by the American College of Rheumatology (ACR) as having the greatest utility in clinical practice because they accurately reflect disease activity; are sensitive to change; discriminate well between low, moderate, and high disease activity; have remission criteria; and are feasible to perform in clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/34\">",
"     34",
"    </a>",
"    ]. The choice of measure is based upon clinician preference; some measures require both patient and clinician input, while others are based only upon patient-reported data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361032#H7361032\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Composite indices for disease activity assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures that require both patient and clinician input, as well as calculators for these measures, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Disease Activity Score derivative for 28 joints (DAS28) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/36/13894?source=see_link\">",
"       calculator 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Simplified Disease Activity Index (SDAI) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?38/51/39733?source=see_link\">",
"       calculator 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The Clinical Disease Activity Index (CDAI) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?26/36/27205?source=see_link\">",
"       calculator 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient-reported outcome measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Routine Assessment of Patient Index Data 3 (RAPID3) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The Patient Activity Scale (PAS) and PAS-II [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The RAPID3 correlates well with the results obtained by use of the DAS28 or CDAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H32342654#H32342654\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'RAPID3 score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111271321\">",
"    <span class=\"h2\">",
"     Symptoms and functional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical assessment of disease activity should include questions concerning the degree of joint pain, the duration of morning stiffness, and the severity of fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]. In addition, evidence for and changes in extraarticular manifestations of RA should be actively sought, including systemic signs such as fever, anorexia, malaise, weight loss, and symptoms of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever is not a common feature of RA in adults. Infection must be excluded before ascribing fever to RA.",
"   </p>",
"   <p>",
"    Patients should be queried regarding their functional capacity, including the performance of activities of daily living, of vocational activities, and of avocational activities. A self-report questionnaire designed to give an assay of function can also be often helpful for this purpose. The Stanford Health Assessment Questionnaire (HAQ) is one of the best known and tested of these questionnaires [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]; others include the Functional Independence Measure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/40\">",
"     40",
"    </a>",
"    ], the Arthritis Impact Measurement Scale (AIMS), the Short Form 36 (SF36), and the Modified Health Assessment Questionnaire (MHAQ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H2#H2\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Functional capacity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We use the evaluation of functional capacity to identify which of a variety of interventions may be required in addition to pharmacologic therapy, especially in patients with diminished functional capacity, such as counseling, exercise, and occupational therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111271346\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physical examination should be performed at regular intervals that vary with disease activity and severity. As an example, patients with severely active disease may be seen at four-week intervals, while those with mildly active or well-controlled disease could be seen every two to four months. At these visits, an examination should be performed to assess changes in previously affected joints or the appearance of inflammation in previously uninvolved joints.",
"   </p>",
"   <p>",
"    A 28 joint examination is appropriate if the hands but not the feet are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/42\">",
"     42",
"    </a>",
"    ]. Examined joints include the wrists, elbows, shoulders, and knees, as well as the metacarpophalangeal and proximal interphalangeal joints of the hands. If the feet are involved, the metatarsophalangeal joints and proximal interphalangeal (PIP) joints of the feet should also be assessed. The joints should be evaluated for the presence of swelling, tenderness, loss of motion, and deformity.",
"   </p>",
"   <p>",
"    In addition to the articular examination, a periodic general physical examination should be performed, with particular attention to the skin for rheumatoid nodules or other dermal manifestations of RA and to the lungs for signs of pleural or interstitial disease, to detect evidence of systemic or extraarticular involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111271371\">",
"    <span class=\"h2\">",
"     Laboratory monitoring of disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute phase reactants, such as CRP or ESR, are useful for assessment of disease activity and are components of several of the formal composite measures used for evaluating the level of disease activity. In addition to these studies, we obtain other tests primarily for medication monitoring that may also reflect changes or levels of disease activity. Examples of the latter include serum hemoglobin, decreases in which may reflect anemia of chronic inflammation, and serum albumin, which may also be reduced in association with increased disease activity. Additionally, platelet counts may be mildly elevated (typically up to 400,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL)",
"    </span>",
"    in patients with ongoing inflammation. (See",
"    <a class=\"local\" href=\"#H111270327\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361018#H7361018\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Acute phase reactants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36616?source=see_link\">",
"     \"Hematologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111271411\">",
"    <span class=\"h2\">",
"     Monitoring and prevention of drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential risks of serious adverse effects and the frequency of common side effects of antirheumatic drugs, a careful balance must be struck between the risks and potential benefits of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. We generally follow the",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/guidelines/recommendations.pdf\">",
"     recommendations of the American College of Rheumatology",
"    </a>",
"    (ACR) for drug monitoring in the treatment of RA (",
"    <a class=\"graphic graphic_table graphicRef78846 \" href=\"mobipreview.htm?13/21/13661\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1,37,45\">",
"     1,37,45",
"    </a>",
"    ]. Additional precautions, warnings, and the manufacturer&rsquo;s recommendations for clinical and laboratory monitoring are provided in the individual UpToDate drug information topics for each medication. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    Monitoring for adverse effects, such as osteoporosis, diabetes, and hypertension, should be performed in patients on glucocorticoids, and appropriate preventive measures should be undertaken. RA is considered an independent risk factor for osteoporotic fracture, and a fracture risk assessment should be performed to help guide treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H2#H2\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Assessment of fracture risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H16#H16\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Monitoring for toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link&amp;anchor=H8#H8\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\", section on 'Liver'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111271451\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of RA, it is appropriate to obtain plain radiographs of the hands and wrists (one film, postero-anterior [PA] view), as well as at least one anterio-posterior (AP) view of both forefeet to include the metatarsophalangeal joints. These radiographs serve as a baseline for evaluating change in the joints during treatment. Radiographs should be repeated every two years in patients in remission or with low disease activity. We view the therapy in use by the patient as insufficient if radiologic evidence of disease progression, such as periarticular osteopenia, joint space narrowing, or bone erosions, appears or worsens during this interval, despite good control of disease activity by other measures. In such patients, based upon our clinical experience, we may intensify or modify the treatment regimen. The clinician must be aware that, in hand radiographs of older patients, coexistent osteoarthritis may account, in part, for joint space narrowing noted near the joints involved with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computerized tomographic (CT) scanning, ultrasonography, computerized image analysis, and magnetic resonance imaging (MRI) are more sensitive for the detection of cartilage and bone abnormalities, and their role in the process of making therapeutic decisions is under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/26,47,48\">",
"     26,47,48",
"    </a>",
"    ]. We do not use these techniques for routine clinical assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6422708\">",
"    <span class=\"h1\">",
"     TIGHT CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the use of tight control treatment strategies to quickly minimize inflammation and disease progression; our therapeutic target is remission or a state of minimal disease activity, without compromising safety. In patients resistant to initial DMARD therapy, we either add additional DMARDs to the ongoing regimen or switch the patient to a different DMARD, while also treating the active inflammation with antiinflammatory drug therapy. A description of our treatment approach and the evidence supporting use of particular medications in patients with active disease despite initial DMARD therapy are discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H169760190\">",
"     'Drug therapy for flares'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with disease exacerbations despite a preceding period of better control of disease activity (a &ldquo;disease flare&rdquo;), a temporary increase in antiinflammatory therapies, including the use of glucocorticoids, may be required. (See",
"    <a class=\"local\" href=\"#H169760190\">",
"     'Drug therapy for flares'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of strategies for tight control involves frequent periodic reassessment of disease activity, usually at least every three months; adjustment of DMARD regimens every three to six months, if needed, as the primary tool to achieve treatment goals; and administration of antiinflammatory therapies (eg, NSAIDs and oral and intraarticular glucocorticoids) as an adjunct to DMARDs to maintain control of disease activity until DMARD therapies are sufficiently effective to discontinue glucocorticoids or to reduce their use to an acceptably low level. Treatment protocols based upon this general approach are associated with improved radiographic and functional outcomes compared with less aggressive approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/6,49-57\">",
"     6,49-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The periodic reevaluation of disease activity using a quantitative composite measure and the use of antiinflammatory drugs, including nonsteroidal antiinflammatory drugs and glucocorticoids, as bridging therapies are both important elements in the strategy of tight control. Glucocorticoids can rapidly achieve control of inflammation until disease-modifying antirheumatic drugs (DMARDs) are sufficiently effective. (See",
"    <a class=\"local\" href=\"#H344392649\">",
"     'Assessment of disease activity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H169759626\">",
"     'Adjunctive role of antiinflammatory agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Taken together, studies that have compared tight control with less aggressive approaches support the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients should receive a DMARD as soon as possible after diagnosis. Achieving and maintaining low disease activity using a DMARD or DMARD combinations as quickly as possible improve long-term outcomes and are cost-effective compared with older, more gradual approaches to initiating DMARD therapy. (See",
"      <a class=\"local\" href=\"#H111269724\">",
"       'Early use of DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excellent treatment responses can be achieved with a wide variety of nonbiologic and biologic DMARDs and with regimens that combine either nonbiologic DMARDs alone or nonbiologic DMARDs with a biologic agent, as described below.",
"     </li>",
"     <li>",
"      Escalation in the treatment regimen is needed for patients resistant to initial treatment; both intraarticular glucocorticoids and oral or intramuscular glucocorticoids help minimize disease activity until DMARDs are sufficient. (See",
"      <a class=\"local\" href=\"#H169759626\">",
"       'Adjunctive role of antiinflammatory agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Regular assessment with composite measures of disease activity is critical to optimize clinical decision-making. (See",
"      <a class=\"local\" href=\"#H344392649\">",
"       'Assessment of disease activity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are reflected in the 2008 and 2012 ACR and 2010 European League Against Rheumatism (EULAR) treatment recommendations and in the recommendations of a 2010 international task force [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1-4,6,58\">",
"     1-4,6,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of tight control have been shown in a meta-analysis of six heterogeneous trials that evaluated tight control strategies in comparison with usual care for RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/59\">",
"     59",
"    </a>",
"    ]. Significantly greater improvement from baseline to one year in the DAS28 composite measure of disease activity was seen in the patients randomly allocated to tight control strategies compared with usual care (mean difference in reduction in DAS28 of 0.59, 95% CI 0.22-0.97). A statistically significantly greater reduction compared with usual care was observed in the trials in which tight control was achieved with protocolized treatment adjustments compared with trials without such protocols (mean difference in DAS28 of 0.91, 95% CI 0.72-1.11, versus 0.25, 95% CI 0.03-0.46). Four of the six studies analyzed compared functional ability in the two treatment arms using the Health Assessment Questionnaire (HAQ). Greater improvement in HAQ scores in the tight control groups that were statistically significant were seen in two of these trials, while improvements in the HAQ scores did not differ significantly between the treatment arms in the other two trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361081#H7361081\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Health Assessment Questionnaire (HAQ)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following trials and related studies best illustrate the range of medications and approaches that support these conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/49-55,60\">",
"     49-55,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       BeSt trial",
"      </strong>",
"      &mdash;In the Behandel-Strategie&euml;n voor Reumatoide Artritis (Dutch for &ldquo;treatment strategies for rheumatoid arthritis&rdquo; or BeSt) trial, 508 patients with early active RA were randomly assigned to sequential monotherapy (group one), to initial monotherapy with step-up combination therapy as required (group two), to combination therapy plus high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (group three), or to combination therapy including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (group four) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Regimens in this trial were adjusted in all groups based upon assessment of disease activity every three months. The next intervention in the defined sequence was assigned if the DAS44 score was &gt;2.4. The treatment sequence in each group was:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Group one (sequential monotherapy) &mdash; Initially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) 15 mg weekly, followed, if needed, by switching sequentially to MTX 25 to 30 mg weekly,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      (LEF), MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , gold plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , and MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      A (CSA) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"     </li>",
"     <li>",
"      Group two (step-up combination therapy) &mdash; Initially MTX 15 mg weekly, followed, if needed, by increasing MTX to 25 to 30 mg weekly, adding SSZ, adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ), adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and switching to MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , to MTX plus CSA and prednisone, and to LEF",
"     </li>",
"     <li>",
"      Group three (initial combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) &mdash; Combination of MTX 7.5 mg weekly plus SSZ and prednisone (60 mg daily tapered gradually to 7.5 mg daily), then MTX 25 to 30 mg weekly plus SSZ and prednisone, MTX plus CSA and prednisone, MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , LEF, gold plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      plus prednisone",
"     </li>",
"     <li>",
"      Group four (initial combination therapy) &mdash; MTX 25 to 30 mg weekly plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per infusion), MTX plus infliximab (6",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      MTX plus infliximab (7.5",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      MTX plus infliximab (10",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      then SSZ monotherapy, LEF monotherapy, MTX plus CSA and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , gold plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      plus prednisone",
"     </li>",
"     <li>",
"      At three months and 12 months, functional improvement was significantly better in those who received initial combination therapy (groups three and four). Significantly less radiographic progression was observed at two and four years in the combination groups compared with the initial monotherapy groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/50,56\">",
"       50,56",
"      </a>",
"      ]. Remission at four years was achieved in 43 percent of all patients, and drug-free remission was seen in 13 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       FIN-RACo trial",
"      </strong>",
"      &mdash;The Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial evaluated the outcomes of 199 patients randomly assigned for at least two years to monotherapy (initially SSZ 2 grams daily) and then sequentially switched every three months, if criteria for an inadequate response were met, to SSZ (3 grams daily), MTX (7.5 to 15 mg weekly),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31476?source=see_link\">",
"       auranofin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , injectable gold,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , or podophyllotoxin (which could be used alternatively after azathioprine), respectively, or to combination therapy (SSZ, MTX, hydroxychloroquine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , with dose adjustment at three months based upon criteria for active disease and with subsequent dose adjustments as needed within defined limits) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The treatment target after the first two years remained remission, but medication choices were not restricted. At follow-up at 11 years following the initial randomization, a significantly greater proportion of patients in the initial combination group had achieved minimal disease activity (63 versus 43 percent) and remission by ACR criteria (37 versus 19 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/54\">",
"       54",
"      </a>",
"      ]. Additionally, radiographic progression at 11 years was significantly less in the group receiving initial combination therapy compared with the group on monotherapy for at least two years (increase in Larsen score of 17, 95% CI 22-33, versus 27, 95% CI 22-33) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       TICORA trial",
"      </strong>",
"      &mdash; In the Tight Control of Rheumatoid Arthritis (TICORA) trial, 111 patients were randomly assigned to intensive or routine management [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/55\">",
"       55",
"      </a>",
"      ]. Intensively managed patients in this trial had monthly visits, with calculation of disease activity scores (a validated composite score based upon the erythrocyte sedimentation rate, Ritchie articular index, joint swelling count, and patients&rsquo; global assessment of disease activity defining high, moderate, and low disease activity levels of &ge;3.6, of &ge;2.4 to &lt;3.6, and of &ge;1.6 to &lt;2.4, respectively); glucocorticoid injections of swollen joints; and, every three months, adjustment of their treatment regimen by a predefined protocol if moderate or highly active disease was present. Routinely managed patients were seen every three months, with no formal measurement of disease activity performed, and glucocorticoid injections and other treatment adjustments were made at the discretion of the rheumatologist.",
"      <br/>",
"      <br/>",
"      After 18 months, the patients receiving intensive management demonstrated a significantly greater decrease in their disease activity scores compared with the routine management group (-3.5 versus -1.9), and a higher proportion achieved a good response by European League Against Rheumatism criteria (82 versus 44 percent). Additionally, physical function assessed by the HAQ was improved to a statistically and clinically significantly greater degree in the patients receiving intensive management (change in HAQ of -0.97 versus -0.47).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169759626\">",
"    <span class=\"h2\">",
"     Adjunctive role of antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use antiinflammatory therapies, including systemic and intraarticular glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs), primarily as adjuncts for temporary control of disease activity in patients in whom treatment is being started with disease-modifying antirheumatic drugs (DMARDs), in patients in whom the DMARD regimen requires modification, or in patients who are experiencing disease flares. Although NSAIDs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoids act rapidly to control inflammation, they do not provide adequate benefit on their own for longer-term control of disease or for prevention of joint injury. More detailed discussions of NSAID and glucocorticoids in RA are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H20661238#H20661238\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Symptomatic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who receive glucocorticoids, we taper the medication as rapidly as tolerated once disease control is achieved and can be maintained, with the ideal goal of discontinuing systemic glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Intraarticular injections of long-acting glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide) are used to reduce synovitis in particular joints that are more inflamed than others. Occasional patients benefit from intramuscular rather than oral administration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is strong evidence that glucocorticoids retard radiographic progression in patients with RA in the short to medium term (ie, up to two years of therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. However, these agents should not be used alone for an extended period. We avoid long-term use, if possible, because chronic use for inflammatory disease is often associated with adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/64\">",
"     64",
"    </a>",
"    ]. However, patients with severe RA sometimes require sustained therapy with low doses of glucocorticoids (less than 10",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    such doses in RA are generally well-tolerated and may have some benefit in retarding disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\", section on 'Efficacy of chronic use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169760190\">",
"    <span class=\"h2\">",
"     Drug therapy for flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA has natural exacerbations (also known as flares) and reductions of continuing disease activity. It is important to distinguish a disease flare, characterized by symptoms and by physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain. Patients with recurrent flares may require adjustment in the background DMARD therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H344392649\">",
"     'Assessment of disease activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The severity of the flare and background drug therapy influence the choice of therapies. The following is a brief summary of glucocorticoid therapy, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to the severity of the flare:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a single or few affected joints, intraarticular glucocorticoid injections may be effective and avoid the need for additional or prolonged systemic therapy.",
"     </li>",
"     <li>",
"      More widespread flares may be treated by initiating glucocorticoid therapy or by increasing the dose of oral glucocorticoid, with the intention of reducing the dose once the flare is under control. The magnitude of dose increase varies with the baseline dose and with the severity of the flare. An alternative to an increase in the oral dose is a single intramuscular injection of depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      acetate.",
"     </li>",
"     <li>",
"      Pulse intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      therapy, usually consisting of three daily infusions of up to 1000 mg, is generally limited to severe flares, particularly those associated with systemic manifestations, such as rheumatoid vasculitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to background drug therapy, an escalation in dose or a modification in drugs is warranted if the patient is flaring frequently or severely. The strategy depends upon the background DMARDs being used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) who will tolerate a slower resolution of their flare may respond to an increase in the dose of MTX or to a switch from oral to subcutaneous therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients initially controlled with a regimen that includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      may benefit from a decrease in the interval of infliximab dosing or from higher doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. However, increasing the dose from 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      was not beneficial in one well-designed trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increases in doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (greater than 50 mg weekly) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (weekly rather than every two weeks), with or without MTX, do not appear to increase efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who require multiple treatment courses with glucocorticoids for recurrent disease flares and whose medication doses have been increased to the maximally tolerated or acceptable level should be treated as patients with sustained disease activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=see_link\">",
"     \"Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2541292\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS IN RA MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of therapeutic decision-making is control of disease activity, as described above, but additional factors, such as the degree of joint injury or disability, may influence the choice of specific therapies in individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Additionally, the efficacy of particular medications may be affected by the presence or absence of some of these factors, which are associated with an adverse prognosis. (See",
"    <a class=\"local\" href=\"#H344394776\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The relative importance of these factors depends upon the individual treatment choice; these are discussed in more detail in the appropriate individual treatment topics. We consider the following factors, depending upon the specific treatment decision:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disability and function &mdash; General scales that measure disability may not identify specific limitations of greater impact on an individual patient. As an example, specific vocational requirements, family responsibilities, or recreational interests may affect a patient&rsquo;s willingness to accept the risks of a given intervention that would help to achieve a greater degree of disease control than low disease activity. We, therefore, incorporate patient-specific needs in our assessment of the severity of disease-related disability.",
"     </li>",
"     <li>",
"      Joint injury &mdash; Good control of disease activity may not result in complete elimination of progressive joint injury in all patients. In patients with low disease activity but with worsening findings on imaging studies, either changes in medications or increased dosing may be of benefit. However, there is insufficient evidence to determine whether treating to targets that are based upon imaging findings provides additional benefit for long-term outcomes, compared with targets based upon measures of disease activity alone.",
"     </li>",
"     <li>",
"      Comorbidities &mdash; The presence of comorbidities, such as renal or hepatic disease, may affect medication choices and may influence the degree of risk inherent in attempting to reach a goal of remission or of low disease activity in a given patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10958831\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical conditions that often coexist with or result from RA may influence the choice of medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1,2,73\">",
"     1,2,73",
"    </a>",
"    ]. (See appropriate treatment and drug information topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344394587\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA often improves or remits completely during pregnancy. Issues related to the pregnant woman with RA, including the use of immunosuppressive drugs, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=see_link\">",
"     \"Rheumatoid arthritis and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10958910\">",
"    <span class=\"h3\">",
"     Lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid pulmonary disease is common in patients with RA and may also be a complication of therapy or of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"     73",
"    </a>",
"    ]. Therapeutic agents with potential for causing adverse pulmonary effects include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , parenteral gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10959059\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid cardiovascular disease can occur in patients with RA and may also be a complication of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"     73",
"    </a>",
"    ]. Both glucocorticoids and NSAIDs may increase cardiovascular risk. TNF inhibitors should be avoided in patients with moderate or severe heart failure (HF), as they can worsen HF. Active RA is associated with an increased risk of cardiovascular disease, but good control of disease activity has been associated with reduced cardiovascular complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31433?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H9#H9\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Cardiovascular effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10959218\">",
"    <span class=\"h3\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic manifestations of RA and the presence of coexistent neurologic disease are generally uncommon, other than the occurrence of impingement neuropathies such as carpal tunnel syndrome. However, TNF inhibitors should be avoided in those with a history of or with an ongoing demyelinating disorder because of case reports of such disorders in patients being treated for RA and because of increased risk of disease worsening in trials of TNF blockade in patients with multiple sclerosis (MS). Some RA experts are also cautious about using TNF-alpha inhibitors in patients with family histories of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11129?source=see_link\">",
"     \"Neurologic manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link&amp;anchor=H17#H17\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Demyelinating disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10959360\">",
"    <span class=\"h3\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of diabetes mellitus is not increased in patients with RA. However, in patients with both diabetes and RA, glucocorticoids should be used with particular caution because they may worsen control of the diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"     73",
"    </a>",
"    ]. In contrast, patients being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or with TNF inhibitors for RA have a lower risk of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/74\">",
"     74",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    may have glucose-lowering effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link&amp;anchor=H22#H22\">",
"     \"Major side effects of systemic glucocorticoids\", section on 'Glucose metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H23#H23\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Reduction of diabetes risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10959471\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA infrequently affects the kidney, but, if renal disease coexists, it increases mortality risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition to NSAIDs, the use of some medications occasionally or only historically used in the treatment of patients with RA may adversely affect renal function, including gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Some nonbiologic DMARDs, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and cyclosporine, should be avoided or used with particular caution in patients with significantly decreased renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37812?source=see_link\">",
"     \"Renal disease in patients with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344394594\">",
"    <span class=\"h2\">",
"     Extraarticular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis has many extraarticular manifestations. The treatment of these specific features, such as vasculitis, interstitial lung disease, and others, is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344394601\">",
"    <span class=\"h2\">",
"     Use of analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that primarily or only provide analgesia, including topical medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    ) and oral agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , and more potent opioids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , hydrocodone), have a limited role in most patients with active disease but may be helpful in patients with end-stage disease and, occasionally, in patients with more severe involvement or during disease flares for added temporary benefit. These medications should not be used as the sole or primary therapy in patients with active inflammatory disease. Apparent need for additional analgesic medications when inflammatory disease is well-controlled (other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or occasional NSAIDs) should prompt a search for alternative comorbid diagnoses, such as fibromyalgia, to explain the patient&rsquo;s symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\", section on 'Inflammatory rheumatic diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344394769\">",
"    <span class=\"h1\">",
"     THERAPY OF END-STAGE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite therapeutic intervention, some patients progress to disabling, destructive joint disease. Symptoms in such patients may be present in the absence of active inflammatory joint disease and may be due to the secondary degenerative changes alone. The accurate evaluation of such patients is essential since deterioration associated with mechanical problems of the muscle or joint is treated much differently from ongoing inflammation or systemic manifestations of RA. Disease exacerbations and their systemic effects are usually easily recognized by the presence of many inflamed joints, fever, anemia, an elevated ESR, or an elevated serum CRP concentration.",
"   </p>",
"   <p>",
"    The goals of therapy in the patient with end-stage disease are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain relief",
"     </li>",
"     <li>",
"      Protection of remaining articular structures",
"     </li>",
"     <li>",
"      Maintenance of function",
"     </li>",
"     <li>",
"      Relief from fatigue and weakness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of inflammation, which requires antiinflammatory medications and DMARDs, treatments other than medications may be particularly important in management. These include nonpharmacologic interventions, such as physical and occupational therapy, use of adaptive devices, and surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37861?source=see_link\">",
"     \"Evaluation and medical management of end-stage rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for surgical intervention in patients with RA include intractable pain or severe functional disability due to joint destruction, as well as impending tendon rupture. The timing of surgery is often critical. If one waits too long, there may be so much muscle atrophy from disuse that postoperative rehabilitation is unsuccessful. On the other hand, a decision about joint replacement should take into account the average life of the artificial joint. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=see_link\">",
"     \"Total joint replacement for severe rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169761721\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS BY MAJOR GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of patients with rheumatoid arthritis (RA) have been developed by major professional organizations, including the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. In addition, an international task force has developed recommendations for treating RA to targeted goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Our approach to treatment is generally consistent with these recommendations. The",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/guidelines/recommendations.pdf\">",
"     2008 ACR recommendations",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/guidelines/Singh et al-ACR RA GL-May 2012 AC&amp;R.PDF\">",
"     2012 update",
"    </a>",
"    can be accessed online.",
"   </p>",
"   <p>",
"    The EULAR recommendations for the management of RA represent a European consensus on the management of RA with DMARDs and glucocorticoids and on the strategies to reach optimal outcomes, based upon evidence and expert opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/4\">",
"     4",
"    </a>",
"    ]. The evidence used was detailed in a series of systematic literature reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/5,76-79\">",
"     5,76-79",
"    </a>",
"    ]. The recommendations include three overarching principles for the care of patients with RA and a set of 15 recommendations covering major issues in disease management. The",
"    <a class=\"external\" href=\"file://ard.bmj.com/content/early/2010/05/04/ard.2009.126532.full.pdf\">",
"     EULAR recommendations",
"    </a>",
"    can be accessed online.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344394776\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA was associated with a high degree of economic loss, morbidity, and early mortality prior to the widespread use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    that began in the 1980s, to more aggressive treatment of early disease, and to the availability of targeted biologic agents since the later part of the 1990s. As an example, almost 80 percent of patients in one center were severely disabled after 20 years of follow-up (from 1967 to 1987); an additional one-third had died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/80\">",
"     80",
"    </a>",
"    ]. Patients with RA that required hospital care had at least a twofold increased mortality when compared with those without disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/81\">",
"     81",
"    </a>",
"    ], and more severe RA was associated with higher mortality rates due to higher rates of myocardial infarction, infection, and certain malignancies, comparable to three vessel coronary artery disease or to stage IV Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical outcomes have improved significantly with changes in drug therapy and in the approach to treatment. The average level of disability in RA was found in a longitudinal study of over 3000 patients to have declined by about 40 percent from 1977 to 1998, even prior to the introduction of the biologic DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/83\">",
"     83",
"    </a>",
"    ]. Similarly, patients with RA seen in a single university clinic from 1984 through 1986 had significantly more disability and greater radiographic evidence of joint injury compared with a cohort from the same clinic seen from 1999 through 2001 (modified Health Assessment Questionnaire disability score on a 0 to 3 scale of 0.4 versus 1, respectively, and Larsen radiographic score on a 0 to 100 scale of 3 versus 20, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients able to achieve remission with combination therapy had significantly less work disability over five years of follow-up compared with patients with incomplete responses to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of factors have been associated with poorer outcomes in patients with RA. The following four markers of adverse prognosis can be used to identify patients who may require more aggressive pharmacotherapy, especially in early stages of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Functional limitation",
"     </li>",
"     <li>",
"      Extraarticular disease",
"     </li>",
"     <li>",
"      Rheumatoid factor positivity or presence of anticyclic citrullinated peptide (CCP) antibodies",
"     </li>",
"     <li>",
"      Bony erosions documented radiographically",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors associated with a worse prognosis include concurrent medical disorders, cigarette smoking, lack of formal education, and lower socioeconomic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/85\">",
"     85",
"    </a>",
"    ]. Older age, female sex, and the presence of the shared epitope have also been associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1\">",
"     1",
"    </a>",
"    ]. Some studies have derived models to estimate prognosis, such as persistent erosive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/11/39098/abstract/86\">",
"     86",
"    </a>",
"    ]. However, these models have not been validated in other cohorts. The individual factors associated with a poor prognosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=see_link\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2403732\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with rheumatoid arthritis (RA), affected areas may be irreversibly damaged or destroyed if inflammation persists. Thus, prompt diagnosis, early recognition of active disease, and measures to quickly achieve and maintain control of inflammation and the underlying disease process, with the goal of remission or low disease activity, are central to modifying disease outcome. The application of these principles in the management of patients with RA, together with the development and use of newer and more potent drugs, has resulted in significant improvement in the outcomes of treatment. (See",
"      <a class=\"local\" href=\"#H6421551\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2703960\">",
"       'Early recognition and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An expert in the care of rheumatic disease, such as a rheumatologist, should participate in the care of patients suspected of having RA and in the ongoing care of patients diagnosed with this condition. The treatment of patients with RA by a rheumatologist is associated with better disease outcomes compared with care rendered primarily by other clinicians. (See",
"      <a class=\"local\" href=\"#H2704646\">",
"       'Care by a rheumatologist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic measures, such as patient education, psychosocial interventions, and physical and occupational therapy, should be used in addition to drug therapy. Other medical interventions that are important in the comprehensive management of RA in all stages of disease include cardiovascular risk reduction and immunizations to decrease the risk of complications of drug therapies. (See",
"      <a class=\"local\" href=\"#H111269512\">",
"       'Nonpharmacologic and preventive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients diagnosed with RA be started on disease-modifying antirheumatic drug (DMARD) therapy as soon as possible following diagnosis, rather than using antiinflammatory drugs alone, such as nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Better outcomes are achieved by early compared with delayed intervention with DMARDs. (See",
"      <a class=\"local\" href=\"#H111269724\">",
"       'Early use of DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of tight control treatment strategies to guide adjustments in the treatment regimen, rather than less aggressive approaches (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Tight control involves reassessment of disease activity on a regularly planned basis with the use of quantitative composite measures and adjustment of treatment regimens to quickly achieve and maintain control of disease activity, if targeted treatment goals (remission or low disease activity), rather than an undefined degree of improvement, have not been achieved. Such tight control treatment strategies are associated with improved radiographic and functional outcomes compared with less aggressive approaches. (See",
"      <a class=\"local\" href=\"#H6422708\">",
"       'Tight control'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H344392649\">",
"       'Assessment of disease activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing prior to therapy should include a complete blood count, erythrocyte sedimentation rate, C-reactive protein, aminotransferases, blood urea nitrogen, and creatinine. Patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      should have a baseline ophthalmologic examination, and most patients who will receive a biologic agent should be tested for latent tuberculosis infection. Screening for hepatitis B and C should be performed in all patients at increased risk of hepatitis. (See",
"      <a class=\"local\" href=\"#H111270327\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use antiinflammatory drugs, including nonsteroidal antiinflammatory drugs and glucocorticoids, as bridging therapies to rapidly achieve control of inflammation until disease-modifying antirheumatic drugs are sufficiently effective. Some patients may benefit from longer-term therapy with low doses of glucocorticoids. (See",
"      <a class=\"local\" href=\"#H169759626\">",
"       'Adjunctive role of antiinflammatory agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RA has natural exacerbations (also known as flares) and reductions of continuing disease activity. The severity of the flare and background drug therapy influence the choice of therapies. Patients who require multiple treatment courses with glucocorticoids for recurrent disease flares and whose medication doses have been increased to the maximally tolerated or acceptable level should be treated as patients with sustained disease activity. Such patients require modifications of their baseline drug therapies. (See",
"      <a class=\"local\" href=\"#H169760190\">",
"       'Drug therapy for flares'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The monitoring that we perform on a regular basis includes testing that is specific to evaluation of the safety of the drugs being used; periodic assessments of disease activity with composite measures; monitoring for extraarticular manifestations of RA, other disease complications, and joint injury; and functional assessment. (See",
"      <a class=\"local\" href=\"#H111270903\">",
"       'Assessment and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors in RA management that may influence the target or choice of therapy include the disabilities or functional limitations important to a given patient, progressive joint injury, comorbidities, and the presence of adverse prognostic factors. (See",
"      <a class=\"local\" href=\"#H2541292\">",
"       'Other considerations in RA management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H344394776\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/1\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/2\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/3\">",
"      Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/4\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/5\">",
"      Knevel R, Schoels M, Huizinga TW, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/6\">",
"      Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/7\">",
"      McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/8\">",
"      Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/9\">",
"      Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/10\">",
"      Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/11\">",
"      Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/12\">",
"      Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/13\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/14\">",
"      Huizinga TW, Pincus T. In the clinic. Rheumatoid arthritis. Ann Intern Med 2010; 153:ITC1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/15\">",
"      Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. Arch Intern Med 1993; 153:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/16\">",
"      Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards. Ann Intern Med 1997; 127:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/17\">",
"      Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. J Rheumatol 1997; 24:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/18\">",
"      Rat AC, Henegariu V, Boissier MC. Do primary care physicians have a place in the management of rheumatoid arthritis? Joint Bone Spine 2004; 71:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/19\">",
"      Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/20\">",
"      van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010; 62:3537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/21\">",
"      Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/22\">",
"      van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/23\">",
"      Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66 Suppl 3:iii2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/24\">",
"      van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/25\">",
"      Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/26\">",
"      Wakefield RJ, Gibbon WW, Conaghan PG, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000; 43:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/27\">",
"      Weidekamm C, K&ouml;ller M, Weber M, Kainberger F. Diagnostic value of high-resolution B-mode and doppler sonography for imaging of hand and finger joints in rheumatoid arthritis. Arthritis Rheum 2003; 48:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/28\">",
"      McQueen FM. The use of MRI in early RA. Rheumatology (Oxford) 2008; 47:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/29\">",
"      Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/30\">",
"      van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/31\">",
"      Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/32\">",
"      Sokka T, M&auml;kinen H. Drug management of early rheumatoid arthritis - 2008. Best Pract Res Clin Rheumatol 2009; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/33\">",
"      Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (&lt;=4 months) versus early rheumatoid arthritis (&gt;4 months and &lt;2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012; 71:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/34\">",
"      Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/35\">",
"      Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010; 62:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/36\">",
"      Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005; 32:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/37\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/38\">",
"      Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/39\">",
"      Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     McDowell I, Newell C. health: A guide to rating scales and questionnaires, 2nd, Oxford University Press, New York 1996. p.106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/41\">",
"      Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001; 28:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/42\">",
"      Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/43\">",
"      O'Dell JR. Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal. Ann Rheum Dis 1996; 55:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/44\">",
"      Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992; 35:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/45\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/46\">",
"      Khanna D, Ranganath VK, Fitzgerald J, et al. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum 2005; 52:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/47\">",
"      Sharp JT, Gardner JC, Bennett EM. Computer-based methods for measuring joint space and estimating erosion volume in the finger and wrist joints of patients with rheumatoid arthritis. Arthritis Rheum 2000; 43:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/48\">",
"      McGonagle D, Conaghan PG, O'Connor P, et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999; 42:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/49\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/50\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/51\">",
"      de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/52\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/53\">",
"      Puolakka K, Kautiainen H, M&ouml;tt&ouml;nen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/54\">",
"      Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/55\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/56\">",
"      van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/57\">",
"      Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009; 151:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/58\">",
"      Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008; 59:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/59\">",
"      Schipper LG, van Hulst LT, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010; 49:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/60\">",
"      Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12:R122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/61\">",
"      Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/62\">",
"      Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; :CD006356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/63\">",
"      Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/64\">",
"      Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/65\">",
"      Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/66\">",
"      Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/67\">",
"      Ariza-Ariza R, Navarro-Sarabia F, Hern&aacute;ndez-Cruz B, et al. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/68\">",
"      Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/69\">",
"      Pavelka K, Jarosov&aacute; K, Such&yacute; D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009; 68:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/70\">",
"      van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 2009; 68:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/71\">",
"      Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006; 33:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/72\">",
"      Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/73\">",
"      Makol A, Wright K, Matteson EL. Safe use of antirheumatic agents in patients with comorbidities. Rheum Dis Clin North Am 2012; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/74\">",
"      Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/75\">",
"      Haas RM, Li P, Chu JW. Glucose-lowering effects of sulfasalazine in type 2 diabetes. Diabetes Care 2005; 28:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/76\">",
"      Gaujoux-Viala C, Smolen JS, Landew&eacute; R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/77\">",
"      Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/78\">",
"      Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/79\">",
"      Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/80\">",
"      Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/81\">",
"      Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/82\">",
"      Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/83\">",
"      Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients. Am J Med 2003; 115:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/84\">",
"      Puolakka K, Kautiainen H, M&ouml;tt&ouml;nen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/85\">",
"      Symmons DP. Environmental factors and the outcome of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/11/39098/abstract/86\">",
"      Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7516 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39098=[""].join("\n");
var outline_f38_11_39098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2403732\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6421551\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2703960\">",
"      Early recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2704646\">",
"      Care by a rheumatologist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111269512\">",
"      NONPHARMACOLOGIC AND PREVENTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13780804\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111270327\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169758115\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111269724\">",
"      Early use of DMARDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111270903\">",
"      ASSESSMENT AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344392649\">",
"      Assessment of disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111271321\">",
"      Symptoms and functional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111271346\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111271371\">",
"      Laboratory monitoring of disease activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111271411\">",
"      Monitoring and prevention of drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111271451\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6422708\">",
"      TIGHT CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169759626\">",
"      Adjunctive role of antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169760190\">",
"      Drug therapy for flares",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2541292\">",
"      OTHER CONSIDERATIONS IN RA MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10958831\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344394587\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10958910\">",
"      - Lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10959059\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10959218\">",
"      - Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10959360\">",
"      - Diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10959471\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344394594\">",
"      Extraarticular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344394601\">",
"      Use of analgesics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344394769\">",
"      THERAPY OF END-STAGE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H169761721\">",
"      RECOMMENDATIONS BY MAJOR GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H344394776\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2403732\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/21/13661\" title=\"table 1\">",
"      Monitoring drug Rx of RA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/36/13894?source=related_link\" title=\"calculator 1\">",
"      Calculator: Rheumatoid arthritis Disease Activity Score (DAS-28)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?38/51/39733?source=related_link\" title=\"calculator 2\">",
"      Calculator: Rheumatoid arthritis Simplified Disease Activity Index (SDAI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?26/36/27205?source=related_link\" title=\"calculator 3\">",
"      Calculator: Rheumatoid arthritis Clinical Disease Activity Index (CDAI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18521?source=related_link\">",
"      Assessing the probability of developing rheumatoid arthritis in patients with undifferentiated inflammatory arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10631?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Epidemiology, pathogenesis, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11129?source=related_link\">",
"      Neurologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33382?source=related_link\">",
"      Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37812?source=related_link\">",
"      Renal disease in patients with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=related_link\">",
"      Rheumatoid arthritis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/6/42090?source=related_link\">",
"      Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_11_39099="Cincinnati Prehospital Stroke Scale";
var content_f38_11_39099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cincinnati Prehospital Stroke Scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The CPSS evaluates for facial palsy, arm weakness, and speech abnormalities. Items are scored as either normal or abnormal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Facial droop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The patient shows teeth or smiles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Normal:",
"        </strong>",
"        Both sides of face move equally.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Abnormal:",
"        </strong>",
"        One side of face does not move as well as the other.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Arm drift",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The patient closes their eyes and extends both arms straight out for 10 seconds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Normal:",
"        </strong>",
"        Both arms move the same, or both arms do not move at all.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Abnormal:",
"        </strong>",
"        One arm either does not move, or one arm drifts down compared to the other.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The patient repeats \"The sky is blue in Cincinnati\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Normal:",
"        </strong>",
"        The patient says correct words with no slurring of words.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Abnormal:",
"        </strong>",
"        The patient slurs words, says the wrong words, or is unable to speak.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Kothari RU, Pancioli A, Liu T, et al. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med 1999; 33:373. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39099=[""].join("\n");
var outline_f38_11_39099=null;
var title_f38_11_39100="Sulfonamide antimicrobial";
var content_f38_11_39100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sulfonamide antimicrobial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 169px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The antimicrobial sulfonamides contain a sulfonamide moiety, an arylamine moiety, and a substituted aromatic ring (R).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39100=[""].join("\n");
var outline_f38_11_39100=null;
var title_f38_11_39101="Transdermal versus oral ERT";
var content_f38_11_39101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Transdermal and oral estrogen prevent bone loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent changes in lumbar spine bone density in postmenopausal women treated with transdermal or oral estrogen replacement therapy (ERT) or not treated. Each estrogen regimen led to an equivalent increase in bone density which was statistically different from the loss of bone in untreated women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women.&nbsp;Lancet 1990; 336:265.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39101=[""].join("\n");
var outline_f38_11_39101=null;
var title_f38_11_39102="Mortality after periprocedural bleeding";
var content_f38_11_39102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    In-hospital (A) and 1-year mortality (B) for patients with peri-procedural bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 544px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the exception of data from the Mayo Clinic, all studies required the occurrence of a blood transfusion to fulfill criteria for peri-procedural bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39102=[""].join("\n");
var outline_f38_11_39102=null;
var title_f38_11_39103="Acute tinea pedis";
var content_f38_11_39103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The medial aspect of the left great toe demonstrates erythematous, papulo-vesicular lesions caused by Trichophyton mentagrophytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_11_39103=[""].join("\n");
var outline_f38_11_39103=null;
